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Pulmonary complications are frequent following hematopoietic stem cell 
transplantation, including infections and pneumonitis. We have used a murine bone 
marrow transplant (BMT) model and murine gammaherpesvirus, γHV-68, to study 
alterations in anti-viral immunity post-transplant. When challenged with γHV-68, BMT 
mice have reduced ability to control lytic viral replication in the lung, despite immune 
reconstitution. By day 21 post-infection the virus is latent, and BMT mice, but not 
control, develop pneumonitis with reduced oxygenation, fibrosis, inflammation, hyaline 
membranes, and foamy alveolar macrophages, a phenotype which persists 7 weeks post-
infection. BMT mice have an increase in cells harvested by bronchoalveolar lavage 
(BAL), and this population is enriched in neutrophils, CD4, and CD8 cells. BAL fluid 
from BMT mice at day 21 has increased pro-fibrotic factors, including hydrogen 
peroxide, nitrite, and transforming growth factor-beta (TGFβ). Defective control of lytic 
virus infection in BMT mice is not related to impaired leukocyte recruitment or defective 
antigen presenting cell function.  Rather, BMT lungs have decreased numbers of 
protective Th1 cells and increased numbers of Th17 cells in response to γHV-68. BMT 
mice are also characterized by an immunosuppressive lung environment at the time of 
infection that includes overexpression of TGFβ1, prostaglandin-E2, and increased Tregs.  
Neither pharmacological blockade of prostaglandin synthesis nor depletion of Tregs 
improved host defense.  To understand the role of TGFβ, BMT mice were transplanted 




(Tcell-DN-TGFβRII) or under the CD11c promoter (CD11c-DN-TGFβRII), blocking 
TGFβ signaling in CD4 and CD8 cells or CD11c-expressing cells, respectively. Tcell-
DN-TGFβRII BMT mice have restored lytic viral load and improved Th1 response; these 
mice are largely protected from the pneumonitis phenotype. However, CD11cDN-
TGFβRII BMT mice show increased susceptibility to lytic infection, similar to wild type 
BMT, and are only moderately protected from pneumonitis. Thus, our results indicate 
that overexpression of TGFβ1 following myeloablative BMT results in impaired T cell 
responses to viral infection, resulting in increased lytic viral load and pneumonitis. Our 
data provide new insight into the potential causes of impaired anti-viral immune 




Chapter 1  
Introduction 
Overview and Hypothesis  
Hematopoietic stem cell transplant (HSCT) is an important therapy used to treat 
several life-threatening diseases. Despite success in disease treatment, transplant 
recipients are at-risk for a number of post-transplant complications, both non-infectious 
and infectious. Pulmonary complications are particularly prominent. Because 
opportunistic infections have been reported to occur late post-transplant in autologous 
HSCT recipients (6, 7), and because functional deficits of immune cell function post-
transplant have been reported in vitro (8-12), we hypothesized that post-transplant 
alterations in immune cell function could contribute to increased susceptibility to virus 
infection post-HSCT. Additionally, based on the recent prospective study showing that 
early post-HSCT virus infection was associated with development of late non-infectious 
pulmonary complications (13), we hypothesized that uncontrolled pulmonary virus 
infection post-HSCT, due to functional deficits in immune cells, could contribute to later 
development of pneumonitis. In these studies, we have used a murine bone marrow 
transplant (BMT) model and murine gammaherpesvirus, γHV-68, to study alterations in 






Hematopoietic Stem Cell Transplantation: Definition 
HSCT involves ablation of hematopoietic cells by chemotherapy and/or total body 
irradiation (TBI) followed by subsequent infusion of self or donor-derived hematopoietic 
stem cells (HSCs), which will repopulate the immune system. Since the first transplants 
were performed in cancer patients in the late 1950s (14, 15), HSCT has become an 
important therapy for the treatment of a number of diseases, including several types of 
malignancies such as multiple myeloma, leukemias, and lymphomas. HSCT may be used 
as a rescue therapy following high-intensity chemotherapy or TBI used to eradicate 
cancer cells. HSCT allows for replacement of non-malignant cells which are also 
destroyed during treatment. Often times in the allogeneic setting, HSCT is used so that 
alloreactive T cells in the graft mediate graft-versus-tumor effects, with the end goal of 
eradicating the cancer (16).  
 HSCT is also an important treatment option for inherited hematological 
disorders, including aplastic anemia, sickle cell anemia, and severe combined 
immunodeficiency (16). Recently, HSCT has been increasingly considered as a 
therapeutic option for severe autoimmune disorders, including systemic sclerosis, 
rheumatoid arthritis, and multiple sclerosis. Randomized clinical trials evaluating the 
effectiveness of autologous HSCT in treating these disorders are ongoing. The immune 
system is thought to “reset” post-transplant, replacing the autoimmune repertoire (17).  
Following conditioning, patients are intravenously infused with HSCs derived 
from bone marrow, umbilical cord blood (18), or mobilized peripheral blood cells from 




(19). In allogeneic transplants, patients receive donor-derived cells, and in autologous 
transplants, which are performed more frequently (20), patients are infused with their 
own cells (harvested and cryopreserved prior to conditioning). These transplanted cells 
will expand and differentiate to fill the niche of the conditioned host. It is estimated that 
30,000 autologous and 15,000 allogeneic transplants are performed annually worldwide 
(16).  
Despite the increasing use of HSCT as a therapeutic option, its effectiveness is 
severely limited by post-transplant complications that lead to significant morbidity and 
mortality in transplant patients. Post-transplant complications, particularly in the lung, 
both infections and non-infectious, are significant barriers to HSCT success.  
Hematopoiesis and Stem Cell Homing 
Cells of the immune system are derived from HSC precursors in the bone marrow, 
a self-renewing population which has the potential to differentiate into nearly all 
hematopoietic cell lineages. HSCs are identified by their expression of the marker CD34. 
HSCs give rise to multipotent progenitor cells, which in turn give rise to the common 
myeloid progenitor (CMP) and common lymphoid progenitor (CLP). Erythrocytes, 
platelets, neutrophils, monocytes, eosinophils, basophils and myeloid dendritic cells are 
ultimately derived from CMP cells. Lymphocytes, including T and B cells, arise 
following multiple differentiation steps from the CLP, as do natural killer (NK) cells and 
plasmacytoid dendritic cells (1, 2) (Figure 1.1). 
Development of both B and T cells involves the genomic rearrangement of 




the main cell types involved in the adaptive immune response, which is able to generate 
immunological memory following activation. T cells develop from CLPs which emigrate 
from the bone marrow to the thymus, where these cells undergo a series of developmental 
steps, resulting in positive and negative selection. B cells undergo development in the 
bone marrow. The diverse antigen specificity of B and T lymphocyte populations is in 
contrast with the more limited, germline-encoded receptors expressed on innate immune 
cells. Innate immune cells recognize antigens via binding to pattern-recognition receptors 
(PRRs), including toll-like receptors (TLR). PRRs recognize general repeated pathogen 
and endogenous danger-associated motifs. Activation of the innate immune system does 
not directly result in generation of immunological memory (21).  
Figure 1.1. Hematopoiesis (Adapted from (1, 2)). HSCs differentiate into 
the multipotent progenitors (MPP), which further differentiate into the 
common myeloid progenitor (CMP) and the common lymphoid 
progenitor (CLP). CMP cells give rise to the megakaryocyte-erythrocyte 
progenitor (MEP) and the granulocyte-monocyte progenitor (GMP). 





The self-renewal and pluripotent capacity of HSCs is demonstrated by a study 
reporting that a single HSC transferred into a lethally irradiated recipient could lead to 
repopulation of the hematopoietic compartment (22). HSCT takes advantage of the ability 
of HSCs to traffic and home from the blood (where they are infused during transplant) to 
the bone marrow niche. The signals involved in the homing of HSCs to the bone marrow 
post-transplant are the same as those involved in initial homing during development. 
Studies have shown that HSC homing is very rapid, occurring within 1-2 hours post-
infusion (23). Homing of HSCs occurs via the expression of the chemokine receptor 
CXCR4 on HSCs, which interacts with SDF-1 expressed on bone marrow endothelium 
and bone marrow stromal cells (23).  
HSCT Conditioning  
Specific conditioning regimens for HSCT vary widely between transplant centers 
and depend on clinical disease course, as well as the health and age of the patient. The 
standard preparative regimen since the 1980s has been a combination of treatment with 
fractioned TBI and cyclophosphamide (16). TBI is given in fractionated doses to reduce 
overall toxicity, and organ shielding may be used to prevent further toxicity. Other 
preparative regimens do not include TBI and involve the use of different 
chemotherapeutic agents including busulfan, sometimes in combination with 
cyclophosphamide (24). Clinical trials indicate that different conditioning regimens may 
be more effective in treatment of different diseases. For instance, a study has shown that 
treatment of myeloid leukemia is similar between groups with or without TBI, but TBI 
was reported to be advantageous to patients receiving HSCT for acute lymphoblastic 




Treating patients with these regimens has several consequences, including 
eradication of malignant or self-reactive cells. Conditioning ablates recipient immune 
cells, providing an immunosuppressed environment for the transplantation of allogeneic 
cells and reducing the risk of graft rejection (24, 25). It has also been suggested that 
conditioning provides a niche for transplanted cells. In the case of malignancy, 
conditioning regimens can break down tumors, releasing tumor antigen to be taken up 
and presented by antigen presenting cells (16).  
Conditioning regimens have historically been myeloablative. More recently, 
reduced-intensity conditioning has been used. Reduced-intensity regimens allow HSCT 
to be performed in older patients and patients with organ dysfunction who could not 
withstand the more intense myeloablative regimens. In the case of malignancy, a balance 
exists between preventing conditioning-associated morbidity and prevention of disease 
relapse by thorough eradication of malignant cells (16). Many of the short and long-term 
complications of HSCT relate to damage caused by conditioning; thus, efforts have been 
focused on adjusting regimens to reduce damage while maintaining all the benefits of 
conditioning.  
Sources of Hematopoietic Stem Cells  
Bone marrow has been the historical source of HSCs for transplantation. To 
harvest bone marrow, donors are given anesthesia, and bone marrow cells are collected 
by repeated aspiration of the posterior iliac crests of the hip (16). Because of the need for 
anesthesia and the pain associated with this procedure, other sources of HSCs have been 




Recently, peripheral blood has become an important source of HSCs, replacing 
bone marrow for most transplants. Blood is a convenient source for HSCs, as cells can be 
harvested by leukapheresis. The normally low numbers of CD34-expressing HSCs in the 
peripheral blood can be substantially increased by treating donors with G-CSF, which 
mobilizes these cells out of the bone marrow and into the circulation (19). The inclusion 
of a small molecule CXCR4 inhibitor can further increase mobilization. CXCR4 is the 
chemokine receptor involved in HSC homing to bone marrow; CXCR4 is expressed on 
HSCs and binds SDF-1 expressed by bone marrow stromal cells and endothelium (26).  
Finally, umbilical cord blood has become an important HSC source. Placental and 
umbilical cord blood can be harvested after birth and frozen prior to transplantation. In 
these transplants, greater HLA mismatches between donor and recipient can be tolerated. 
However, the use of cord blood for HSCT is associated with slower engraftment and thus 
greater risk of infectious complications. Additionally, the use of cord blood can be 
limited by low numbers of cells harvested, though recent studies have investigated the ex-
vivo expansion of cord blood-derived HSCs (16, 18).  
Cell infusions used for transplantation are generally complex mixtures of HSCs 
and mature hematopoietic cells which are present in the donor bone marrow, peripheral 
blood, or cord blood. Therefore, grafts may include mature T cells. Inclusion of mature T 
cells in grafts promotes immune reconstitution and, in the allogeneic setting, promotes an 
immune response of grafted cells against malignant cells (27). Greater numbers of T cells 
are found in peripheral blood-derived grafts, thus increasing the graft-versus-tumor 
effect. This is in contrast with cord blood grafts, which contain relatively few T cells. 




disease (GVHD), where engrafted allogeneic T cells are activated against recipient 
antigens, causing severe tissue and organ damage. In allogeneic transplants for the 
treatment of malignant diseases, there is a balance between promoting alloreactive T cell 
responses against host malignant tissue and preventing alloreactive T cell-mediated 
destruction of normal host tissue.  
Complications of HSCT 
Despite promising success in the treatment of many diseases, the efficacy of 
HSCT is limited due to significant transplant-related morbidity and mortality. There are a 
wide variety of complications that can occur following HSCT, both non-infectious and 
infectious. Many complications persist long-term post-transplant, and this is most clearly 
demonstrated in pediatric HSCT survivors who are at-risk for a myriad of long-term side 
effects (28). Complications can be related to consequences of the conditioning regimen, 
the development of acute and chronic GVHD mediated by alloreactive T cells, or the 










Pulmonary Complications of HSCT 
Pulmonary complications comprise a large group of post-transplant complications 
and are reported to occur in up to 60% of HSCT recipients (29); one study of 82 deceased 
HSCT recipients found pulmonary complications in 89% of the cohort (30). Additionally, 
HSCT patients have been reported to have abnormal pulmonary function tests long-term 
post-transplant (31, 32).  The frequent occurrence of pulmonary complications in HSCT 
recipients may be associated with toxic effects of both TBI (33, 34) and 
chemotherapeutic agents (35) on lung tissue. Infectious and non-infectious pulmonary 
complications post-HSCT are outlined in Figure 1.2. 
Figure 1.2 Pulmonary complications post-HSCT (adapted from (2, 3)). This diagram 
outlines a subset of infectious and non-infectious pulmonary complications which have 




Two major non-infectious pulmonary complications of HSCT are bronchiolitis 
obliterans and idiopathic pneumonia syndrome (IPS). Bronchiolitis obliterans involves 
airflow obstruction and occurs almost exclusively in the allogeneic setting (36). 
Bronchiolitis obliterans is thought to be a pulmonary manifestation of GVHD, where 
alloreactive donor T cells are activated against host antigens (37). Symptoms of IPS 
mimic infectious pneumonia (36), with mortality occurring in 60-80% of cases. There are 
currently no effective therapies for the treatment of IPS, but some recent studies have 
shown success using etanercept, blocking TNF in IPS treatment (38). The pathogenesis of 
IPS is not well understood, and it is likely that the disease is multi-factorial, including the 
effects of conditioning, GVHD, inflammatory cell recruitment, cytokine production and 
possibly undiagnosed infection (36, 38, 39). IPS is notably more frequent in the 
allogeneic setting; however, several studies have reported its occurrence in a significant 
percentage of autologous transplant recipients (36, 40, 41), suggesting that the 
mechanism for this complication is likely multi-factorial.  
A recent prospective study of pediatric allogeneic HSCT recipients closely 
monitored respiratory viral infections post-transplant and found that early respiratory 
virus infection post-transplant was correlated significantly with development of IPS and 
bronchiolitis obliterans in their cohort. Importantly, patients had recovered from their 
initial respiratory symptoms prior to development of later respiratory complications 
associated with IPS or bronchiolitis obliterans (13). It is interesting to speculate that an 
inflammatory stimulus, such as a virus, can lead to pneumonitis and lung injury at later 
time points, even after resolution of the initial lytic insult. Work presented in this 




Infectious complications can occur in both allogeneic (42) and autologous 
recipients (43, 44), though they are more common in allogeneic transplants (29), 
presumably due to GVHD and immunosuppressive drug therapy to prevent or treat 
GVHD. Pulmonary infections post-HSCT can be caused by fungi, bacteria, and viruses 
(45). Invasive fungal infections in the lungs in HSCT patients are principally caused by 
Aspergillus and Candida species (46, 47), and bacterial pneumonia is reported to be 
caused by Pseuodomonas aeruginosa, Klebsiella pneumonia, and Legionella (48). Viral 
pneumonia in HSCT patients can be caused by herpesviruses, including cytomegalovirus 
(CMV) varicella zoster (VZV), human herpesvirus-6 (HHV-6), Epstein-Barr Virus 
(EBV) and herpes simplex virus (HSV), as well as other viruses, including influenza, 
adenovirus, and respiratory syncytial virus (4, 45, 49). Historically, CMV infection was 
the most significant viral complication of HSCT; mortality rates of CMV pneumonia in 
HSCT recipients were near 85% prior to the development of anti-viral drug therapy (50). 
Despite advances in prophylaxis and antiviral therapy, however, CMV disease remains a 




Infectious complications in HSCT recipients are characterized by when they occur 
post-HSCT, including pre-engraftment (during neutropenia, 1 month post-HSCT), early 
post-engraftment, and late post-engraftment (approximately 3 months post-transplant) (3, 
48, 52). Figure 1.3 summarizes infections reported to occur during these post-transplant 
time periods (4).   
 
Impaired Immune Responses Post-Transplant 
The occurrence of severe infectious complications in HSCT recipients is 
indicative of immunosuppression post-HSCT. While infectious complications are 
common prior to engraftment of immune cells, patients continue to be susceptible even 
late post-engraftment (Figure 1.3). This is partially explained by the administration of 
Figure 1.3 Timeline of infectious complications post-HSCT (4). Specific bacterial, viral, and 





immunosuppressive drug therapy in allogeneic transplant recipients as an effort to control 
development of GVHD. However, opportunistic infections have been reported to occur 
late post-transplant in autologous patients as well (6, 7). This fact suggests that 
conditioning and subsequent transplantation, even in the absence of immunosuppressive 
therapy and GVHD, can lead to immune dysfunction post-transplant.  
Indeed, several studies have shown impaired cellular immune responses in HSCT 
recipients. Reconstitution of immune cell subset numbers occurs within the first few 
months post-transplant, with innate populations such as NK cells, macrophages, and 
neutrophils reconstituting prior to adaptive immune cells (8, 53). Although NK cells have 
been reported to be largely functional post-HSCT, both neutrophils and macrophages 
have been reported to have diminished function post-HSCT (8). B cell numbers 
reconstitute in peripheral blood within the first 4 months post-transplant. Despite normal 
proliferative responses to mitogen stimulation, these cells produce little to no isotype-
switched antibody within the first year post-HSCT (9). In transplant patients, the total 
number of CD3+ T cells reconstitutes in peripheral blood by several months post-
transplant; however, the ratio of CD4 to CD8 cells in peripheral blood is inverted, with 
increased CD8 and decreased CD4 numbers (8, 54-56). In the months following 
transplant, peripheral T cells are thought to be expanded by homeostatic proliferation, 
leading to a limited T cell repertoire in HSCT patients, which has been reported to persist 
even 3 years post-transplant (56). In addition to limited T cell repertoire, several studies 
have reported deficiencies in peripheral T cell function post-HSCT using in vitro assays 
of T cell function. T cells from autologous HSCT recipients were shown in one study to 




leukocyte reaction (MLR); T cell proliferation to these stimuli did not reach pre-
transplant levels even 1 year post-transplant (10). Other studies have found similar 
decreases in proliferation in response to anti-CD3, anti-CD2 and PHA stimulation (11, 
12). One group found a greater reduction in frequencies of mitogen-responsive T cells 
from peripheral blood of autologous recipients compared to allogeneic (57), suggesting 
that immunodeficiency post-HSCT is not solely related to graft-versus-host effects.  
Taken together, studies of immune reconstitution in HSCT patients suggest that 
significant alterations in immune cell phenotype and function occur following transplant. 
Mechanisms for these alterations have not been completely elucidated for each cell type 
and may depend on the type of transplant, clinical disease course, or the specific time 
post-HSCT.  
Murine Models of Bone Marrow Transplant  
The wide variety of indications, conditioning regimens, and variations in 
protocols among transplant centers and patients complicate the understanding of 
mechanisms of immune dysfunction in HSCT patients. The development of a small 
animal model of HSCT has been critical for controlled study of the mechanisms of 
impaired immunity post-transplant. Murine models of HSCT typically involve TBI 
followed by bone marrow transplantation (BMT) between inbred mouse strains (58). One 
major advantage of murine BMT models is the ability to use transgenic mice as BMT 
donors or recipients in order to understand roles of specific genes in transplantation. The 
large number of inbred mouse strains also allows for the development of several 




genetically identical donors and recipients) models autologous transplant and, 
furthermore, allows for study of conditioning and transplantation in the absence of the 
confounding effects of GVHD or immunosuppressive drug therapy. Another important 
advantage of murine BMT models is the ability to study function of tissue-resident 
hematopoietic cells; human studies are largely limited to studying functions of cells 
derived from peripheral blood.  
Innate Immune Defects in Murine BMT  
Our laboratory has previously used murine BMT to understand alterations in 
innate immune responses to pulmonary bacterial infections post-transplant. These studies 
have established a syngeneic BMT model wherein transplanted mice are more susceptible 
to lung infection by Pseudomonas aeruginosa, despite having completely restored their 
hematopoietic compartment in both the periphery and the lung. Transplanted mice have 
increased bacterial burden in the lung and bacterial dissemination to the blood at 24 hours 
following intratracheal infection when compared with non-transplanted control mice (59). 
This inability to control P. aeruginosa infection is related to dysfunctional innate immune 
responses, including defective phagocytosis and killing of bacteria by alveolar 
macrophages and defective bacterial killing by lung neutrophils. Alveolar macrophages 
also produce reduced levels of the proinflammatory cytokine TNFα (60).  
In this model, lungs from BMT mice overproduce the immunosuppressive lipid 
mediator prostaglandin E2 (PGE2), which impairs innate immunity to P. aeruginosa (60).  
When BMT mice are treated with indomethacin, a cyclooxygenase inhibitor which blocks 




observed in non-transplant control mice. Additionally, indomethacin treatment can 
restore function of BMT alveolar macrophages and neutrophils in vitro (60). Recent data 
suggest that PGE2 suppresses alveolar macrophage function by inducing the upregulation 
of IL-1R-associated kinase (IRAK)-M in these cells, thus inhibiting MyD88-dependent 
signaling responses. Bacterial clearance, phagocytosis, and TNFα production can be 
restored in the BMT setting by using IRAK-M knock-out mice as BMT donors (61).  
Murine Gammaherpesvirus-68 
For studies in this dissertation, we chose to use a murine gammaherpesvirus as a 
model pathogen to understand how anti-viral may be altered following murine BMT. 
Murine gammaherpesvirus-68 (γHV-68; also known as MuHV4 or MHV-68) is a double-
stranded DNA virus with genetic similarity to the human gammaherpesviruses, Epstein-
Barr Virus and Kaposi’s Sarcoma Associated Herpesvirus (also known as human 
herpesvirus-8). Its genome consists of 118, 237 base pairs, encoding approximately 100 
viral genes (62). Although γHV-68 was first isolated from bank voles in Slovakia (63), it 
is able to establish infection in laboratory mouse strains, thus making γHV-68 infection in 
mice an important model for understanding of gammaherpesvirus pathogenesis in vivo 
(64, 65).  The natural route of γHV-68 infection has not been definitively established, 
though it is thought to be via the respiratory route. 
When delivered intranasally to mice, γHV-68 establishes an acute, lytic infection 
primarily in respiratory epithelial cells, which lasts approximately 10 days. Viral 
replication peaks approximately 6-9 days post-infection, and lytic replication is largely 




establishes a chronic infection by establishing latency primarily in splenic B cells, but 
data from our laboratory show that the virus also persists in lung fibroblasts, epithelial 
cells, macrophages, and B cells (64, 67). γHV-68 infection can persist for the life of the 
host, with presumed periodic reactivation from latency. Only under conditions of 
immunosuppression does γHV-68 cause disease in the infected host.  
Similar to EBV infection, γHV-68 induces the development of infectious 
mononucleosis and splenomegaly. This involves the expansion of polyclonal B cell 
populations, as well as expansion of CD8 T cells which express the Vβ4 T cell receptor 
(66). Splenomegaly peaks approximately 2 to 3 weeks after initial acute infection. 
Thereafter, the number of latently infected splenocytes normalizes to steady-state; it has 
been estimated that 1 in 10
5
 to 1 to 10
6
 splenocytes maintain latent infection (68). During 
persistent infection, γHV-68 reactivation is largely prevented by adaptive immune 
responses; however, some viral reactivation is thought to occur. The mechanisms of 
reactivation are not clearly described; however, TLR ligation has been suggested (69). 
Interestingly, several studies have indicated that the latent viral load does not correlate 
with the degree of viral replication during acute infection (70, 71). One study found 
equivalent levels of latency in the spleen in mice challenged with an initial intranasal 
viral dose ranging from 40 to 4x10
5
 pfu (72).  
γHV-68 expresses several genes which are important for its pathogenesis, and 
these genes are differentially expressed during lytic replication and viral latency. During 
lytic replication, γHV-68 expresses several genes, including its viral DNA polymerase 
gene and the viral capsid glycoprotein gene gB (73), as well as ORF50, which encodes 




genes have been identified as important in the establishment of viral latency, including 
mLANA, which functions to maintain the viral episome. ORF72 is a Cyclin D homolog 
which is required for viral reactivation from latency. Other viral gene products have been 
found to promote viral immune evasion, including K3, which targets MHC Class I 
proteins for ubiquitination and M3, a CC chemokine-binding protein (69).  
Immune control of γHV-68 involves interplay between many cell types. The 
immune response to γHV-68 involves activation of CD4, CD8, and B cells, and each of 
these cell types is important in controlling γHV-68 replication in vivo. Studies have 
revealed that C57BL/6 mice deficient in CD4 cells have increased viral titers and develop 
a chronic wasting disease (74). While C57BL/6 mice lacking CD8 cells or B cells also 
have increased viral titers, these mice do not develop disease from infection (65, 75, 76). 
The relative contribution of each cell type seems to depend on the specific inbred mouse 
strain. Several studies have established that IFNγ production by CD4 cells specifically is 
critical for control of lytic replication (77-79) and that CD4 cells have direct effector 
function (as opposed to controlling infection via providing help to CD8 cells) (75, 76). 
Natural killer cells do not seem to play a critical role in controlling γHV-68 infection, 
though these cells are activated during γHV-68 infection (80, 81). The cytokine 
environment during acute γHV-68 infection is dominated by proinflammatory, Th1 type 
cytokines, including IFNγ, IL-6, IL-1β, IL-10, and TNFα (66).  
Data from our laboratory have shown that in the lung, γHV-68 latency alters 
production of proinflammatory and profibrotic mediators in several cell types. Lung 
fibroblasts, alveolar macrophages, and B cells isolated from latently infected mice all 




growth factor (TGF)β relative to saline-treated control mice. Additionally, increased 
chemokine and TNFα expression were reported in latently-infected cells (67). These data 
indicate that virus latency alters the immune and inflammatory environment of the 
persistently infected host.  
Transforming Growth Factor-Beta 
TGFβ is an important pleiotropic cytokine produced by leukocytes, including 
lymphocytes, antigen presenting cells and NK cells (82), as well as structural cells (83). It 
has multiple roles in embryonic development, cellular migration, differentiation, and the 
immune system. While TGFβ1 is the prototypical TGFβ family member, there are three 
isoforms of TGFβ expressed in mammals (TGFβ1, -β2, and -β3) (84). Each of these is 
secreted in the latent form, non-covalently associated with a homodimer of the latency-
associated peptide (23, 85), which is capable of inhibiting TGFβ activity (86). LAP, in 
turn, can be linked by disulfide bonds to the latent-TGFβ-associated protein which allows 
the whole latent TGFβ complex to be associated with the extracellular matrix (85). TGFβ 
must be released from its latent form, disassociating from LAP, in order to function. 
There are several ways in which TGFβ can become activated including proteases (87), 
integrins (88), or change in pH (89). TGFβ1 is the main isoform with effects on the 
immune system.  
Activated TGFβ dimers mediate their functions via serine/threonine kinase 
receptors. TGFβ receptors are expressed on a wide variety of cells, including 
hematopoietic cells. TGFβ binds the transmembrane TGFβ type II receptor (TGFβRII), 




ALK5 is not required for initial TGFβ binding, but it is required for signal transduction to 
occur. After ALK5 becomes phosphorylated, it will then phosphorylate and activate 
SMAD  proteins. Receptor-associated SMAD 2 and 3 and Co-SMAD-4 translocate to the 
nucleus to arbitrate changes in gene expression via recruitment of transcription factors 
and binding the SMAD-binding element (82, 90) (Figure 1.4). TGFβ has also been 
reported to signal in a SMAD-independent process (82).  
 
Figure 1.4. SMAD-dependent TGFβ signaling (adapted from (82, 91)). Active TGFβ 
dimers bind TGFβRII. Upon ligand binding, TGFβRII phosphorylates ALK5. 
Phosphorylated ALK5 then phosphorylates the receptor-associated SMADS, R-SMAD2 
and R-SMAD3. These phosphorylated R-SMADs then associate with Co-SMAD4, which 
allows the complex to translocate to the nucleus. Here, the complex binds the SMAD-
binding element (92) and associates with transcription factors (93) to mediate changes in 






Effects of TGFβ on Hematopoietic Cells  
TGFβ has been reported to have both immunosuppressive and immunostimulatory 
functions, even on the same cell types, and these functions appear to be context-
dependent (82, 94).  Most strikingly, TGFβ is known to be critical for maintenance of 
peripheral tolerance, as TGFβ knock-out (KO) mice develop severe inflammation and 
autoimmunity (95, 96). In addition to being a known T cell chemoattractant (97), TGFβ  
can also act on T cells to limit their proliferation (98) and their differentiation into Th1 
and Th2 phenotypes, subsets of helper T cells characterized by production of the 
cytokines IFN-γ and IL-4, respectively (99, 100).  TGFβ-mediated inhibition of naïve T 
cell proliferation can be attributed in large part to its ability of inhibit transcription of IL-
2 (101); addition of exogenous IL-2 to T cell cultures treated with TGFβ can restore T 
cell proliferation (albeit not completely) (98). Inhibition of Th1 differentiation has been 
shown to be due to the ability of TGFβ to inhibit transcription of Tbet, the transcription 
factor required for Th1 development (102). TGFβ treatment blocks Th2 differentiation by 
blocking expression of GATA-3, the Th2-associated transcription factor (82). Studies 
using transgenic mice expressing a DN-TGFβRII in T cells and mice with a T-cell 
specific deletion in the tgfbr1 gene indicate that both the ability of T cells to signal in 
response to TGFβ and produce TGFβ are critical in prevention of T cell-mediated 
autoimmunity (103, 104). These studies described a decisive role for TGFβ in dampening 
T cell activation and differentiation.  
In contrast, TGFβ1 in conjunction with IL-6 can induce the differentiation of 
naïve CD4 T cells into the IL-17a- producing Th17 phenotype (105).  TGFβ1 can also 




immunoregulatory T cells which can be identified by expression of the transcription 
factor Foxp3 and are critical for maintenance of peripheral tolerance (106, 107). The 
importance of TGFβ in Treg differentiation was first shown by its ability to convert 
naïve, CD25- CD4 T cells to Foxp3-expressing Tregs in vitro (106). The ability of TGFβ 
to induce Treg expansion in vivo was shown in a murine model of autoimmune diabetes; 
in this study, intraislet injection of TGFβ was sufficient to induce expansion of Tregs and 
prevent disease (107).  
Although TGFβ signaling has been shown to inhibit B cell proliferation and 
inhibit IgG serum immunoglobulin levels (108), it also promotes IgA production which is 
essential for protection of mucosal sites (108).  Indeed, conditional inactivation of the 
TGFβ receptor in B cells leads to a reduction in antigen-specific antibody responses 
following immunization at mucosal sites (109).  
With respect to innate immune cells, TGFβ acts as a chemoattractant for 
neutrophils (110) and monocytes (111).  Additionally, TGFβ can induce these cells to 
produce the proinflammatory cytokine IL-1β (111).  In contrast, macrophage activation 
can be limited by the presence of TGFβ1 and -β2, and NK cell function is also limited by 
TGFβ (112, 113). TGFβ can limit both NK cell homeostasis and NK cell production of 
IFNγ, as evidenced by studies performed in mice expressing a DN-TGFβRII construct 
under the CD11c promoter(114). Table 1.1 summarizes some of the known effects of 
TGFβ on hematopoietic cells.  
As a result of its pleiotropic functions and potent effects of hematopoietic cells, 




the Th1 response would limit immunity to pathogens such as viruses and intracellular 
parasites, while TGFβ has been shown to be beneficial in the immune response to fungal 
infections (82).  
Table 1.1 Effects of TGFβ on Immune Cells (adapted from (5)) 
Stimulatory Inhibitory 
With IL-6 induces Th17 (105) Decreases T cell proliferation, activation 
(98, 104) 
Promotes Treg differentiation (106) Decreases Th1 and Th2 (99, 100) 
Increases IgA production (109) Decreases B cell proliferation and IgG 
production (108) 
Increases monocyte, neutrophil, 
lymphocyte and mast cell chemotaxis 
(97, 110, 111, 115) 
Decreases macrophage activation and NK 
function (112, 113) 
 
Regulation of TGFβ post-HSCT  
The production of TGFβ post-HSCT has been shown to be affected by the 
conditioning regimens used to prepare HSCT recipients for transplant. During the 
conditioning period, an initial drastic reduction in serum TGFβ1 levels was shown to 
occur in both autologous and allogeneic HSCT recipients (116), and TGFβ1 levels in the 
plasma of allogeneic HSCT recipients underwent a 4-fold decrease (117). This pattern 
was also noted in a mouse model of allogeneic transplant, where total serum TGFβ was 
greatly reduced 7 days post-transplant (118). Serum TGFβ levels in both allogeneic and 
autologous patients were shown to return to normal levels between 20 and 50 days post-
transplant, and this recovery correlated with the return of white blood cell and platelet 




Production of TGFβ in other sites post-HSCT has been reported to be increased. 
TGFβ mRNA transcripts were found to be elevated in skin biopsies of patients 
experiencing cutaneous GVHD (119).  Additionally, high dose irradiation can stimulate 
overproduction of TGFβ1 in the human lung (34).  In a murine model of allogeneic 
HSCT, TGFβ transcript levels in the lung were shown by in situ hybridization to be 
increased relative to that of non-transplanted control mice at day 7 post-transplant; 
including cyclophosphamide in the pre-HSCT conditioning regimen potentiated this 
increase (118).  Taken together, these studies suggest that production of TGFβ is 
dysregulated following conditioning and HSCT, though TGFβ production by individual 
cell types post-transplant has not been analyzed in a systematic study.  
Because of the pleiotropic nature of TGFβ, the potential effects of its 
dysregulation post-HSCT are likely to be complex and contradictory. Studies have shown 
that although TGFβ may limit acute GVHD (117, 120), it may also contribute to the 
development of chronic GVHD and fibrosis (120, 121).  Early post-allogeneic HSCT, the 
presence of TGFβ may prevent graft rejection and thus promote graft acceptance (122). 
The role of TGFβ in host defense post-HSCT is also complex. While there are potentially 
beneficial effects in terms of leukocyte recruitment (97, 110, 111, 115) and IgA 
production (109), there is also evidence from a murine BMT model indicating that TGFβ 
can directly promote virus-induced pneumonitis (123, 124).  Potential effects of TGFβ 




Pulmonary Fibrosis and TGFβ   
Organ injury and fibrosis are detrimental complications of HSCT. Fibrosis is 
characterized by dysregulated deposition of extracellular matrix (ECM) proteins such as 
collagen, ultimately leading to organ scarring and failure. The fibrotic process in the lung 
can be initiated following epithelial cell injury, where mesenchymal cells including 
fibroblasts and myofibroblasts produce collagen and other ECM proteins. Pulmonary 
fibrosis can occur as a complication of HSCT (3).  TGFβ, as a central molecule in the 
pathogenesis of fibrotic disease (121), is a potential biomarker for development of 
fibrotic complications. TGFβ1 can stimulate collagen deposition by fibroblasts and 
myofibroblasts leading to fibrosis (83). Furthermore, the ability of TGFβ1 to induce 
alpha smooth muscle actin expression in lung myofibroblasts also leads to alveolar 
contraction, which further limits gas exchange (125). 
Figure 1.5  Potential effects of TGFβ post-HSCT (5). TGFβ is a 
pleiotropic cytokine with a complex role in the immune system. 
Dysregulation of TGFβ post-HSCT has several potential effects, both 





Patients who developed pulmonary fibrosis as a result of autologous transplant for 
treatment of breast cancer had increased levels of plasma TGFβ prior to transplant 
conditioning when compared to patients who did not develop disease and healthy controls 
(126). The role of transplant-induced TGFβ in the induction of fibrotic disease following 
HSCT in humans has not been evaluated; however, irradiation injury has been shown to 
induce TGFβ1 in both human and animal lungs (34, 124, 127).  Taken together, these 
data strongly support a role for TGFβ in mediating the fibrotic complications which occur 
late post-HSCT.   
Pulmonary fibrosis is thought to be mediated by several pro-fibrotic factors in 
addition to TGFβ. Oxidative stress, including production of reactive oxygen and nitrogen 
species, has been implicated in contributing to pulmonary fibrosis in both human (128) 
and murine (129) studies. Indeed, reactive nitrogen intermediates have been shown in 
animal studies to stimulate production of TGFβ (130). The mechanisms by which 
reactive oxygen intermediates may promote fibrosis include their ability to activate the 
transcription factors NFкB and AP-1, promoting inflammation, and their ability to 
directly degrade ECM components (131). In addition, one study has shown that low 
levels of hydrogen peroxide can promote proliferation of human fibroblast cell lines in 
vitro (132). Activation of the coagulation cascade has also been shown to promote 
pulmonary fibrosis (133).  
Alternatively Activated Macrophages 
Alveolar macrophages are the cell type which comprises the large majority of 




can be activated to one of two general phenotypes: classical activation or alternative 
activation. Classically-activated macrophages are pro-inflammatory cells which express 
inducible nitric oxide synthase (iNOS), and their phenotype is induced by IFNγ. 
Alternatively activated macrophages are phenotypically and functionally distinct from 
classically activated macrophages. These cells play a role in the normal wound repair 
process and have been shown to promote fibrosis. Alternatively activated macrophages 
are identified by expression of arginase-1, an enzyme which promotes collagen 
production and fibroblast proliferation (134, 135).  Alveolar macrophages from idiopathic 
pulmonary fibrosis patients and in a murine model of γHV-68-induced pulmonary 
fibrosis have been shown to express arginase-1 (136). In this chronic γHV-68-induced 
pulmonary fibrosis model in IFNγ receptor knock-out mice, the alveolar macrophages 
were reported to be histologically large and foamy (136). Development of alternatively 
activated macrophages is thought to be largely dependent on the production of Th2-type 
cytokines, including IL-4 and IL-13 which can both directly induce alternative activation 
(135).  
γHV-68 and Fibrosis  
Infection with γHV-68 has been reported to potentiate the development of fibrosis 
in several murine model systems. γHV-68-infected IFNγ receptor KO mice develop 
multi-organ fibrosis (137), and splenic fibrosis in these mice has been related to the 
development of alternatively activated macrophages expressing the pro-fibrotic gene 
arginase-1 (138). Additionally, the development of γHV-68-induced pulmonary fibrosis 




macrophages in disease pathogenesis (136). In both of these cases, the Th2-skewed 
nature of the mouse likely contributed to the alternative activation of the macrophages. 
Studies from our laboratory have shown the ability of γHV-68 infection to 
augment pulmonary fibrosis in wild type mice. γHV-68 can cause increased collagen 
deposition, fibrocyte recruitment, and diminished lung function when given to mice with 
established pulmonary fibrosis due to intratracheal instillation of fluorescein 
isothiocyanate (139). Additionally, mice develop more severe disease if given fibrotic 
challenge following γHV-68 infection and latency compared to uninfected mice (140). 
Potential mechanisms include virus-induced upregulation of pro-fibrotic factors, 
including TGFβ, which persist during viral latency (67).  
Antigen Presenting Cells 
Antigen presenting cells (APCs) are critical for development of an effective 
adaptive immune response to pathogens. Dendritic cells are considered to be professional 
APCs and the key cell type which bridges innate and adaptive immune responses. The 
current paradigm holds that immature dendritic cells in the tissues sample their 
environment by macropinocytosis and present antigens on surface MHC molecules. 
Dendritic cells can become activated upon recognition of a pathogen via PRRs, including 
TLR stimulation. Mature dendritic cells then migrate from the periphery to secondary 
lymphoid tissues, where they express high levels of MHC Class II and upregulate the 
costimulatory molecules CD80, CD86, and CD40, among others, which are important for 




priming in the lymph node is thought to, in turn, promote specific programs of cytokine 
production by T cells.   
Dendritic cell numbers may remain reduced even at 1 year post-HSCT (142). The 
functionality of these cells post-HSCT may depend on the stem cell source, as cord 
blood-derived dendritic cells may have decreased MHC and adhesion molecule 
expression. While some studies have indicated that monocyte-derived dendritic cells 
from HSCT patients have reduced costimulatory and MHC expression (143), other 
studies have shown no reduced functionality. One study of autologous HSCT patients 
found that at six months post-transplant, these cells had even more potent antigen-
presenting capacity than dendritic cells generated from the patients prior to transplant 
(10).  Dendritic cell-based immunotherapies are being considered in the HSCT context, in 
terms of inducing tolerogenic responses to alloantigens and, conversely, promoting anti-
tumor responses, as well as in promoting anti-pathogenic responses (142).  
Helper T Cell Differentiation 
Naïve CD4 cells (Th0) can differentiate into cytokine-producing Th1, Th2, and 
Th17 helper T cell subsets, generally characterized by the hallmark cytokines they 
produce, though recent studies have shown a degree of plasticity which exists between T 
cell subsets (144, 145). Cytokine signals from APCs, such as dendritic cells, at the time 
of T cell activation are thought to be important in skewing CD4 cells toward specific 
lineages.  
Th1 cells are characterized by production of their hallmark cytokine, IFNγ, as 




of IL-12p35 and IL-12p40) and are affirmed through subsequent IFN-γ production. Th2 
cells are thought to be induced by IL-4, and these cells produce IL-4, IL-13, and IL-5, 
among others. Th1 cells express the transcription factor Tbet, while Th2 cells express 
GATA-3; these two transcription factors are known to be mutually antagonistic. Th17 
cells, identified by IL-17a, IL-17f, and IL-22 production, can be induced by TGFβ in 
conjunction with pro-inflammatory cytokines such as IL-6 or IL-1β (146). Th17 cells are 
also defined by expression of the transcription factors RORγt and RORα. Figure 1.6 
diagrams the general paradigm regarding differentiation of naïve T cells. Naïve CD4 T 
cells can also differentiate into regulatory T cells, which are discussed in the next section. 
 
Figure 1.6. Helper T cell differentiation (Adapted from (147)). Undifferentiated CD4 T 
cells (Th0) can be skewed by the cytokine environment to adopt specific transcription 





Studies have indicated that alterations in T cell differentiation occur post-
autologous HSCT. In addition to reduction in IL-2 production by peripheral T cells post-
HSCT, it has been reported that upon in vitro stimulation with PHA and PMA, PBMCs 
from autologous transplant recipients produce significantly reduced IFNγ and IL-4 within 
6 months post-engraftment (148). Whether these alterations have functional impact on 
immune responses to pathogens has not been evaluated.  
Regulatory T Cells 
Tregs are a specific subset of CD4 cells which function to suppress immune 
responses of effector T cells. Tregs can develop through the thymus (natural or nTregs) 
and are broadly defined by constitutive expression of the high-affinity IL-2 receptor, 
CD25, as well as the transcription factor Foxp3, CTLA-4 and GITR (149). Tregs can also 
develop in the periphery, as naïve CD4 cells can be induced to gain suppressive function 
(inducible or iTregs). TGFβ has been shown to convert naïve CD4 cells to Tregs and 
induce the expansion of these cells (106). Tregs play an important role in maintaining 
peripheral tolerance and immune homeostasis, preventing T cell mediated autoimmunity, 
as mice and humans deficient in Foxp3 develop multi-organ autoimmunity (149). The 
mechanisms by which Tregs mediate their immunosuppressive functions have not been 
definitively described, but studies indicate that production of TGFβ and IL-10 are 
important for Treg-mediated suppression (150).  
In the setting of HSCT, Tregs have been best described in their ability to induce 
graft tolerance and suppress GVHD (151). It has also been suggested that Treg 




populations expand post-HSCT. One study showed a significant increase in the percent 
CD4+Foxp3+ cells in the bone marrow of multiple myeloma patients following 
allogeneic HSCT compared to newly diagnosed multiple myeloma patients and healthy 
donors (152). Accordingly, Foxp3 mRNA expression in peripheral CD4 cells was found 
to be increased  post-transplant (compared to pre-transplant and donor levels) in a cohort 
of elderly patients despite receiving CD25-depleted allografts (153).  Increased 
frequencies of CD4+CD25
hi 
Tregs were also reported in the peripheral blood of chronic 
myeloid leukemia patients that had undergone allogeneic HSCT compared to newly 
diagnosed patients and healthy controls; functionally, these cells were more effective at 
suppressing T cell proliferation in an in vitro assay as compared to healthy donors (154).  
In a mouse model of experimental BMT, it was shown that the host Treg population in 
the spleen could expand following transplant and that these host-derived cells could 
persist for months post-transplant (155).  
The potent ability of Tregs to suppress effector T cell responses allows the 
possibility that upregulation of Tregs post-HSCT may impact T cell-mediated immunity 
and contribute to the infectious complications which occur post-transplant. However, one 
recent study demonstrated that adoptive transfer of Tregs into mice receiving an 
allogeneic BMT could limit GVHD, but did not impair the ability of the BMT mice to 
respond to lethal CMV infection (156).  
Rationale for Virus Infection Studies in BMT Mice  
Due to advances in prophylaxis, detection, and anti-viral therapy, infectious 




51). Improved outcomes, however, are dependent on treatment with anti-viral drugs, and 
the emergence of viral strains that are resistant to drug therapy (157, 158) highlights the 
need to better understand the underlying immune responses that occur in transplant 
patients.  
Because opportunistic infections have been reported to occur late post-transplant 
in autologous HSCT recipients (6, 7), and because functional deficits of immune cell 
function post-transplant have been reported in vitro (8-12), we hypothesized that post-
transplant alterations in immune cell function could contribute to increased susceptibility 
to virus infection post-HSCT. Additionally, based on the recent prospective study 
showing that early post-HSCT virus infection was associated with development of late 
non-infectious pulmonary complications (13), we hypothesized that uncontrolled 
pulmonary virus infection post-HSCT, due to functional deficits in immune cells, could 
contribute to later development of pneumonitis.  
To test these hypotheses, we chose to use a murine BMT model and pulmonary 
infection with γHV-68. Studies were performed using a syngeneic BMT model, which 
allows for controlled study of how conditioning and subsequent transfer of cells leads to 
alterations in immune responses following cellular reconstitution. This model provides 
insight into immune changes that occur as result of conditioning and transplantation 
alone, in the absence of GVHD and immunosuppressive drug therapy. Additional 
preliminary studies were performed to confirm results in a fully allogeneic BMT model. 
We chose to use well-studied murine herpesvirus, γHV-68, as a model pathogen for these 





Our studies establish a murine BMT model in which mice have increased 
susceptibility to pulmonary gammaherpesvirus infection in the absence of GVHD or 
immunosuppressive therapy, following reconstitution of immune cell numbers. 
Additionally, in our model, BMT mice develop severe gammaherpesvirus-induced 
pneumonitis, with pathological features similar to idiopathic pneumonia syndrome, which 
occurs during viral latency. Our model reveals alterations in immune cell responses and 
changes in cytokine production by hematopoietic and structural cells post-HSCT, which 
contribute to the impaired anti-viral response. Our data provide new insight into the 
potential causes of impaired anti-viral immune responses and development of 




Chapter 2  
Materials and Methods  
Mice 
C57BL/6 and CD4KO mice were purchased from The Jackson Laboratory (Bar Harbour, 
ME). Mice expressing dominant negative TGFβ receptor II under the permissive CD4 
promoter backcrossed to the C57BL/6 background (104) were bred at the University of 
Michigan and obtained from Dr. Keith Bishop. Due to the nature of the promoter 
construct, these mice lack functional TGFβ receptor II in both CD4 and CD8 T cells 
(104).  Mice expressing the same construct under the CD11c promoter (114), provided by 
Dr. Yasmina Laouar, were bred at the University of Michigan. IL-10KO and IL-17aKO 
mice were obtained from Dr. Weiping Zou at the University of Michigan. Mice were 
housed in specific pathogen-free conditions and were monitored daily by veterinary staff. 
Experiments were approved by the University of Michigan Committee on the Use and 
Care of Animals.  
Bone Marrow Transplantation 
We performed syngeneic BMT as described previously (59, 60, 161). Recipient mice 
were treated with 13 to 13.5 Gy of total body irradiation using a 
137
Cs irradiator, 
delivered in two doses separated by 3 hours.  5x10
6
 donor whole bone marrow cells from 
a genetically identical donor in 0.2 mL Dulbecco’s Modified Eagle Medium (DMEM; 




injection.  Mice were given acidified water (pH 3.3) for the first three weeks post-BMT. 
Total numbers of hematopoietic cells were fully reconstituted in the lungs and spleen at 5 
weeks post-BMT, with lung lymphocytes being 93% donor-derived at this time point 
(161).   In some experiments, B6Ly5.2 mice purchased from the Fredrick Cancer 
Research Facility (Fredrick, MD) were used as bone marrow donors for irradiated 
B6Ly5.1 (Jackson Laboratory) recipients so that donor vs. host leukocytes could be 
distinguished by staining for the CD45.1 (Ly5.2) and CD45.2 (Ly5.1) alleles using 
antibodies commercially available from BD PharMingen (San Diego, CA). All infections 
were performed at 5 to 6 weeks post-BMT. Allogeneic transplants (C57BL/6  Balb/c or 
Balb/c  C57BL/6) were performed in the same manner as syngeneic transplants. At 5 
weeks post-BMT, both total lung cell numbers and lung CD4 T cell numbers were 
reconstituted in these mice. In some experiments, mice were conditioned with reduced 
intensity radiation (6.5 or 9 Gy). 
γHV-68 Infection  
γHV-68, clone WUMS, (5x10
4
 plaque-forming units (pfu); American Type Culture 
Collection, Manassas, VA) was diluted in 20 μl of phosphate-buffered saline (PBS) and 
delivered intranasally (i.n.) to mice which had been anesthetized with ketamine and 








Quantification of lytic virus from right lungs of mice was determined by plaque assay, as 
described previously (139).  Briefly, right lungs were dissected from mice 7 days after 




supplemented with Complete protease inhibitor (Sigma, St. Louis, MO).  Supernatants 
from right lung homogenates were diluted and placed in triplicate on sub-confluent 
monolayers of 3T12 cells (American Type Cell Culture Collection); plaques were 
enumerated 7 days later.  
Real Time Reverse-Transcriptase Polymerase Chain Reaction 
Real-time reverse transcriptase–polymerase chain reaction (RT-PCR) was performed on 
an ABI Prism 7000 thermocycler (Applied Biosystems, Foster City, CA) using a 
previously described protocol (60).  Gene-specific primers and probes (Table 2.1) were 
designed using Primer Express software (Applied Biosystems). Each reaction contained 
12.5 µl Taqman 2x Universal PCR Mix (Applied Biosystems), 0.625 µl 40x MultiScribe 
and RNase Inhibitor Mix (Applied Biosystems), 0.25 µM Taqman FAM/TAMRA-
labeled probe, 0.3 µM forward primer, 0.3 µM reverse primer, 300 ng RNA and DEPC-
treated water to give a final volume of 25 µl. Relative expression was determined using 
the delta delta Ct method (162), using β-actin as a control gene.  
Table 2.1 Primers and probes for real time RT-PCR 
Gene Oligo Sequence 
DNA polymerase (ORF9) F. primer ACAGCAGCTGGCCATAAAGG 
  R. primer TCCTGCCCTGGAAAGTGATG 
  Probe CCTCTGGAATGTTGCCTTGCCTCCA 




  R. primer ACCACGCCCTGGACAACTC 
  Probe TTGCCTATGACAAGCTGACCACCA 
β-actin F. primer CCGTGAAAAGATGACCCAGATC 
  R. primer CACAGCCTGGATGGCTACGT 
  Probe TTTGAGACCTTCAACACCCCCAGCCA 
M3 F. primer AGTGGGCTCACGCTGTACTTGT 
 R. primer TGTCTCTGCTCACTCCATTTGG 
 Probe CATGGGCAAGTGTTCATCTTAGCC 
Collagen 1 F. primer TGACTGGAAGAGCGGAGAGTACT 
 R. primer GGTCTGACCTGTCTCCATGTTG 
 Probe CTGCAACCTGGACGCCATCAAGG 
Collagen 3 F. primer GGATCTGTCCTTTGCGATGAC 
  R. primer GCTGTGGGCATATTGCACAA 
 Probe TGCCCCAACCCAGAGATCCCATTT 
iNOS F. primer ACATCAGGTCGGCCATCACT 
 R. primer CGTACCGGATGAGCTGTGAAT 




Arginase-1 F. primer ACCACAGTCTGGCAGTTGGAA 
 R. primer GCATCCACCCAAATGACACA 
  Probe CTGGCCACGCCAGGGTCCAC 
 
Histology 
Lungs were harvested for histology as previously described (163). Lungs from euthanized 
animals were perfused with PBS, inflated with 1 mL of 10% neutral buffered formalin, 
removed, and fixed for 6-24 hours in formalin. Lungs were dehydrated in ethanol for at 
least 24h, embedded in paraffin and cut into 3-µm sections. Sections were placed on 
slides and stained with hematoxylin and eosin (H&E) or Masson’s Trichrome Blue for 
collagen deposition.  
Pathology Scoring 
H&E and Trichrome-stained slides were analyzed by a pulmonary pathologist in a 
blinded fashion. Lungs were scored for the severity of fibrosis, perivascular 
inflammation, and peripheral inflammation on a scale of 0 (absent) to 3 (severe). The 
presence of foamy alveolar macrophages and hyaline membranes was graded as 0 
(absent) or 1 (present). The scores for each parameter were totaled to give a pathology 





Figure 2.1. Pathology scoring system.  
 
Oxygen Saturation Measurements 
Oxygen saturation was measured using a MouseOx Pulse Oximeter according to the 
manufacturer’s instructions (Starr Life Sciences Corp., Oakmont, PA). Mice were 
anesthetized and neck hair was removed using a depilatory cream. 24 hours later, collar 
clip sensors were placed on awake mice, and oxygen saturation was measured as an 
average over 15 seconds per mouse.  
Bronchoalveolar Lavage (BAL)   
BAL was performed as previously described, with modifications (60). Cells were isolated 
from the alveolar space by lavaging with 20 mL of PBS containing 5mM EDTA in 
successive 1 mL aliquots. BAL fluid (BALF) was harvested by instilling 1 mL of PBS 
containing 5mM EDTA into lung and removing fluid by suction; BALF was centrifuged 






Measurement of Reactive Oxygen Species 
Samples were assayed for hydrogen peroxide using the Amplex Red Hydrogen Peroxide/ 
Peroxidase Assay Kit (Invitrogen Molecular Probes, Inc., Eugene, OR) and for nitrite 
using the Griess Reagent System (Promega Corporation, Madison, WI) following the 
manufacturer’s instructions.  
Flow Cytometry 
For some experiments, whole lungs or right lungs were prepared for flow cytometry by 
collagenase digestion, as described previously (164).  1x10
6
 – 2.5 x10
6
 cells were stained 
for flow cytometry using fluorochrome-conjugated antibodies against the cell surface 
markers CD45, CD4, CD8, CD19, NK1.1, TCRβ, CD11c, I-A
b
, and CD25 (BD 
Pharmingen, San Jose, CA) following incubation with anti-CD16/CD32 (FcBlock, BD 
Pharmingen).  Forkhead box protein 3 (Foxp3) staining was performed using PE Anti-
Mouse/ Rat Foxp3 Staining Set (eBioscience, San Diego, CA), following the 
manufacturer’s instructions. For intracellular cytokine staining, cells were first stimulated 
with phorbol 12-myristate 13-acetate (PMA, Sigma, 0.05 μg/mL) and ionomycin (Sigma, 
0.75 μg/mL) for 6 hours in the presence of Golgi Stop protein transport inhibitor (BD 
Pharmingen). Anti- IL-17a antibody was obtained from BD Pharmingen, and anti-IFNγ 
from eBioscience. For collagenase-digested lung cells, gates were first set on CD45-
expressing cells followed by gating on the lymphocyte-sized subset when appropriate. 






Mixed Leukocyte Reactions 
Mixed leukocyte reactions (MLRs) were performed as described, with modifications 
(92). 2x10
5
 stimulator (irradiated, 1.6 Gy) and 1, 2, or 4x10
5
 responder cells were co-
cultured in a 96-well plate for 4 days in RPMI-1640 (Hyclone Laboratories, Inc., Logan, 
UT) supplemented with 10% FCS.  1 μCi of 
3
H- thymidine was added for the last 18 
hours of culture.  Proliferation was determined by subtracting counts per minute (cpm) of 
responders alone from cpm in wells containing both responders and stimulators. For 
some experiments, bone marrow derived dendritic cells (BMDCs) were used as 
stimulators.  BMDCs were prepared as described (165), with modifications.  Total bone 




 cells in 100 mm Petri dishes containing 10 mL 
RPMI-1640 and 20 ng/mL GM-CSF (Peprotech, Rocky Hill, NJ). Cells were fed an 
additional 10 mL of media and GM-CSF at day 3, and non-adherent BMDCs were 
harvested from the plates at day 7.  In other experiments, whole spleen cells were used as 
stimulators. Responder cells were either total spleen cells or CD4 cells magnetically 
purified from the spleen using MACS CD4 (L3T4) MicroBeads (Miltenyi Biotech, 
Auburn, CA).  BMDCs were stained for expression of I-A
b
, CD80 and CD86 using 
antibodies from Pharmingen. 
Alveolar Epithelial Cell (AEC) Isolation 
Type II AECs were isolated using dispase and DNase digestion of lungs as previously 
described (166, 167).  Bone marrow-derived cells were removed via anti-CD32 and anti-
CD45 magnetic depletion.  Mesenchymal cells
 
were removed by overnight adherence in a 
petri dish.  Non-adherent
 
cells were plated at 1x10
6




had been previously coated with fibronectin for 72 h.  The media was changed to serum-
free media and supernatants were collected 24 h later for determination of TGFβ1 levels 
by ELISA. Immunohistochemical staining of AEC preparations revealed cells were 
>94% positive for e-cadherin with less than 3% contamination by vimentin-positive 
mesenchymal cells. 
Viral Genome Quantification  
DNA was prepared from γHV-68-infected lungs using the Qiagen DNeasy Blood and 
Tissue Kit (Valencia, CA), and real time PCR was performed to detect viral gB DNA as 
previously described (67, 168). Values were compared to a standard curve consisting of 
gB plasmid DNA diluted at known copy numbers. Reported values were normalized to 
100 ng of input DNA for each reaction. For gB DNA analysis, the forward primer was 
5’GGCCCAAATTCAATTTGCCT, the reverse primer was 
5’CCCTGGACAACTCCTCAAGC and the probe was 5’6-(FAM)-
ACAAGCTGACCACCAGCGTCAACAAC-(TAMRA). 
Viral Immunohistochemistry 
Frozen lung sections were prepared from infected mice and γHV68 was detected using a 
rabbit polyclonal anti- γHV68 sera (169) provided by Dr. Skip Virgin (Washington 
University School of Medicine, St. Louis, MO). Staining was detected with a goat anti-







Whole lungs were homogenized in 1 mL PBS supplemented with Complete protease 
inhibitor (Sigma); homogenates were spun down and resulting supernatant or cell culture 
supernatants were assayed for cytokines using the DuoSet ELISA Development System 
kits (R&D Systems, Minneapolis, MN) following the manufacturer’s instructions.  For 
TGFβ1 ELISAs, samples were acid-treated and then neutralized in order to activate 
TGFβ prior to assay. Prostaglandin E2 (PGE2) was measured using an EIA kit from 
Cayman Chemicals (Ann Arbor, MI) according to manufacturer’s instructions. 
Regulatory T cell (Treg) Depletion 
Treg depletion was performed by giving mice a single intraperitoneal (i.p.) injection of 
100 μl anti-CD25 ascites (PC61) at 4 weeks post-BMT. Control mice were given 100 μg 
isotype control antibody.  
Reagents Used 
Complete media is DMEM (Lonza, Walkersville, MD) with 10% fetal bovine serum 
(Fisher, Pittsburgh, PA), 1% penicillin-streptomycin (Gibco/Invitrogen, Carlsbad, CA), 
1% L-glutamine (Fisher) and 0.1% amphotericin B (Lonza). Serum-free media is DMEM 
with 1% bovine serum albumin (Sigma, St. Louis, MO), 1% penicillin-streptomycin, 








Statistical significance between 2 groups was measured by Student’s t-test using 






Chapter 3  
Results 
BMT mice have increased viral loads at d7 post-infection with γHV-68  
In order to understand whether BMT mice were more susceptible to 
gammaherpesvirus infection following transplant and immune reconstitution, we first 
infected syngeneic BMT mice at 5 weeks post-transplant with 5x10
4
 pfu γHV-68 i.n. For 
comparison, we also infected naïve, non-transplanted control mice. We then harvested 
whole lungs from both groups at d7 post-infection, a time point near the peak of lytic 
virus replication. Left lungs were harvested for RNA, and expression of lytic viral genes 
was determined using real time RT-PCR. Expression of both the envelope glycoprotein 
gene gB (Figure 3.1A) and viral DNA polymerase (Figure 3.1B) was significantly 
increased in lungs from BMT mice compared to non-transplanted control mice. To 
confirm increased susceptibility to viral infection, right lungs were harvested for plaque 
assay to quantify lytic viral load. Again, BMT mice displayed significantly higher levels 
of lytic virus compared to non-transplanted control mice (Figure 3.1C). 
Immunohistochemistry on frozen lung sections using polyclonal anti-γHV-68 serum 







Figure 3.1. BMT mice have higher viral burden in the lungs at d7 post-infection 5 weeks 
following BMT.  Control and syngeneic BMT mice were infected i.n. with 5x10
4
 pfu 
γHV-68 5 weeks following BMT.  A. and B. At d7 post-infection, left lungs were 
processed for RNA and expression of lytic viral genes was measured using real time RT-
PCR. Expression of the viral capsid gene gB and viral DNA polymerase was significantly 
increased (p=0.0085 and p=0.0089, respectively) in the lungs of BMT mice when 
compared to non-transplanted controls (data combined from 2 experiments). C. At d7 
post-infection, right lungs from BMT and control mice were harvested for plaque assay 
(p=0.0014, n=10 control, 9 BMT, data combined from 2 experiments). D. Frozen 
sections of lungs from control and BMT mice were prepared at day 7 post-infection and 
were stained with rabbit polyclonal antisera against γHV68 or with non-immune rabbit 
sera as control. The goat anti-rabbit secondary was linked to alkaline phosphatase. 





These studies were performed using a myeloablative conditioning regimen (1350 
rads) which our laboratory previously described to result in maximum reconstitution of 
the lung by donor-derived leukocytes (170). To determine whether the increased 
susceptibility to γHV-68 post-BMT was related to myeloablative conditioning, we next 
transplanted mice using three conditioning regimens (650, 900, and 1350 rads). At 5 
weeks post-transplant, mice were infected with 5x10
4
 pfu γHV-68. At d7 post-infection, 
lungs were harvested for RNA, and expression of the lytic viral genes, gB and DNA 
polymerase, was determined using real time RT-PCR. Expression of both the capsid gene 
and DNA polymerase increased with higher irradiation dose, reaching statistical 
significance in the mice conditioned with 1350 rads (Figure 3.2).  
 
Figure 3.2 Increased susceptibility to γHV-68 depends on myeloablative conditioning. 
Control and BMT mice at 5 weeks post-BMT (conditioned with 650, 900, or 1350 rads) 
were infected i.n. with 5x10
4
 pfu γHV-68. At d7 post-infection, lungs were processed 
for RNA and expression of lytic viral genes was measured using real time RT-PCR. 
Expression of the viral capsid gene gB and viral DNA polymerase was significantly 
increased (p=0.0085 and p=0.0017, respectively) in the lungs of BMT mice conditioned 
with 1350 rads when compared to non-transplanted controls (n=at least 9 mice per 




We next determined whether the increased susceptibility of BMT mice to γHV-68 
infection was also dependent on the dose of virus. To test this, BMT and control mice 
were challenged with three doses of γHV-68. At d7 post-infection, lungs were harvested 
for RNA and relative expression of the viral capsid gene and viral DNA polymerase were 
determined using real time RT-PCR. Relative expression of both genes increased in the 
BMT lungs compared to non-transplant controls with increasing virus dose (Figure 3.3).  
Figure 3.3. BMT mice show increased susceptibility to γHV-68 when challenged 







 pfu of γHV-68. At day 7 post-infection, left lungs were harvested, 
processed for RNA, and expression of viral genes was analyzed by real time RT-
PCR. Expression in control lungs was normalized to 1 for each viral dose. A. 
Expression of viral DNA polymerase was significantly increased in the lungs of 




 pfu γHV-68. B. Expression of the viral 
capsid gene gB was significantly increased in the lungs of BMT mice challenged 





BMT and control mice have equivalent latent viral loads by d21 post-infection 
Based on the conditioning and dose-titration experiments, subsequent studies 
were carried out using myeloablative conditioning and 5x10
4
 pfu γHV-68. Following i.n. 
infection in immunocompetent mice, lytic replication of γHV-68 in the lungs largely 
subsides by d14; by d21 post-infection, latency is established with very little viral 
replication occurring (140). To determine the course of virus infection in BMT mice 
beyond the peak lytic phase, lungs were harvested from BMT and control mice at days 14 
and 21 post-infection with 5x10
4
 pfu γHV-68. Lungs were then analyzed for expression 
of viral transcripts and levels of viral genome were quantified.  Using real time RT-PCR 
on lung RNA, we found that expression of the viral genes K3 and M3  (which can be 
expressed during both lytic infection and latency) were significantly increased in BMT 
lungs compared to control at d14 (Figure 3.4A, B). To confirm this increase, we 
harvested DNA from lungs at d14 post-infection and quantified copy numbers of the viral 
genome using real time PCR and a plasmid standard containing known copy numbers of 
gB DNA (Figure 3.4C). There was a trend towards increased viral genomes in BMT 
mouse lungs at d14. 
At d21 post-infection, relative mRNA expression of the lytic/ latent viral gene M3 
was expressed at significantly higher levels compared to the lytic viral gene gB, 
suggesting that γHV-68 was predominantly latent at this time point in both BMT and 
control mice. Additionally, we found no significant difference between levels of either 
gene in lungs of BMT or control mice (Figure 3.5A). To confirm that there was no 
difference in latent viral load, we harvested DNA from lungs at d21 post-infection and 




significant difference in quantities of viral genomes between BMT and control mice 
(Figure 3.5B). Thus, by three weeks post-infection, γHV-68 infection is latent and latent 







Figure 3.4 BMT mice have increased viral load at d14 post-infection with γHV-
68. Control and BMT mice were infected with 5x10
4
 pfu γHV-68 i.n.  A. and B. 
At d14 post-infection, lungs were harvested for RNA and expression of the viral 
genes K3 and M3 was measured using real time RT-PCR. Expression of both 
genes was significantly increased in BMT lungs. C. At d14 post-infection, lungs 
were harvested for DNA and copy number of viral gB gene was quantified using 





   
Figure 3.5 BMT and control mice have similar latent viral load at d21 post-infection 
with γHV-68. Control and BMT mice (5 weeks post-transplant) were infected with 5x10
4
 
pfu γHV-68 intranasally. A. At d21 post-infection, lungs were harvested for RNA and 
expression of the lytic viral capsid gene gB and the predominantly latent viral gene M3 
were measured using real time RT-PCR. There was no significant difference in 
expression of either of these genes between BMT and control mice. Expression of M3 
was significantly increased over gB in both control and BMT lungs (p=0.0002 and 
p=0.0081, respectively) (n=11 mice per group; data combined from 2 experiments). B. 
At d21 post-infection, lungs were harvested for DNA and copy number of viral gB gene 
was quantified using real time PCR using a standard with known quantities of gB DNA. 
There was no significant difference in latent viral genome load between BMT and 




BMT mice develop severe virus-induced pneumonitis and fibrosis during virus latency  
Because of the differences in viral load noted in BMT mice at days 7 and 14 post-
infection, we hypothesized that there might be differences in the inflammatory response 
to the lung between control and BMT mice. To test this hypothesis, lungs were harvested 
for histology and H&E staining at days 7, 14, and 21 post-infection with 5x10
4
 pfu γHV-
68. We found similar infiltration of inflammatory cells between BMT and control mice at 
d7 post-infection (Figure 3.6A). However, at d14 and d21 post-infection, BMT mice 
develop a severe pneumonitis response not seen in the control setting (Figure 3.6B, C). 
Magnified lung sections at d21 post-infection show filling of the alveolar space with 
inflammatory cells, as well as evidence of diffuse alveolar damage and destruction of the 
alveolar architecture (Figure 3.7). Additionally, damaged airway epithelial cells are 









Figure 3.6 BMT mice develop severe pneumonitis during virus latency. 
BMT and control mice were infected i.n. with 5x10
4
 pfu γHV-68. At 
days 7, 14, and 21 post-infection, lungs were harvested for histology and 
sections were stained with H&E. Sections shown are representative of 








Figure 3.7 Pneumonitis is increased following γHV-68 infection in BMT mice.  
Non-transplant control mice (panels A, C) or mice at 5 weeks post-BMT 
(panels B, D) were infected with 5x10
4
 pfu γHV-68 and lungs were analyzed 
for histology 21 days post-infection. 400x magnification of H&E stained lung 
sections reveals alveolar filling, evidence of diffuse alveolar damage and 
destruction of alveolar architecture in BMT mice (B), as well as damaged 




Because of the severe inflammatory phenotype and lung damage observed in 
BMT mice at d21 post-infection, and due to data implicating γHV-68 as a factor for 
fibrosis development in murine models (136, 139, 140), we hypothesized that BMT lungs 
may be fibrotic during virus latency. Lung sections from control and BMT mice at days 
7, 14, and 21 post-infection with 5x10
4
 pfu γHV-68 were stained with Trichrome to 
determine collagen deposition. Trichrome-stained lung sections indicated mild to 





Figure 3.8 BMT mice develop lung fibrosis during virus latency. BMT and 
control mice were infected i.n. with 5x10
4
 pfu γHV-68. At days 7, 14, and 21 
post-infection, lungs were harvested for histology and sections were stained 
with Trichrome for collagen deposition (in blue). Sections shown are 





Increased collagen in BMT lungs was confirmed at d21 post-infection by real 
time RT-PCR. Collagen 1 and collagen 3 transcripts were increased approximately 2 fold 
in BMT lungs compared to control lungs (Figure 3.9).  
 
H&E and Trichrome-stained slides were analyzed in a blinded fashion by a 
pulmonary pathologist, and lungs from BMT mice were shown to have mild to moderate 
fibrosis, foamy alveolar macrophages, peripheral inflammation, and diffuse alveolar 
damage. Both control and BMT mice showed perivascular inflammation (Figure 3.10A). 
Figure 3.9. BMT lungs have increased collagen expression during latent 
γHV-68 infection. BMT and control mice were infected with 5x10
4
 pfu 
γHV-68 and lungs were harvested at d21 post-infection. Lungs were 
harvested for RNA, and expression of collagen 1 and collagen 3 was 
analyzed using real time RT-PCR. Expression was normalized to a 
control mouse for each gene. Collagen 1 and collagen 3 were 
significantly increased in BMT lungs (p=0.0348 and p=0.0129, 





In order to quantify the histologic changes, lungs were scored on a scale of 0 (normal 
lung) to 11 (most severe pathology) based on the presence and severity of these 
pathological features, as described in Materials and Methods (Figure 2.1). BMT mice had 
a significant increase in histology score at days 14 and 21 post-infection compared to 
control mice (Figure 3.10B).  
Figure 3.10. BMT mice display distinct pathological features at d21 post-
infection with γHV-68. A. H&E and Trichrome-stained lung sections from BMT 
and control mice at d21 post-infection with γHV-68 were analyzed for presence 
of pathological features in a blinded fashion by a lung pathologist (n=5 control, 
4 BMT; representative of at least 3 independent experiments). B. Lung sections 
were scored on the basis of presence and severity of pathological features, and a 
composite score was generated for each mouse. A mean histology score was 
generated for each group (n=2 d7 Control and BMT, 3 d14 Control and BMT, 





 To determine whether the pathology observed in BMT mice was virus-induced or 
due to the conditioning regimen alone, lung sections from uninfected BMT mice at 8 
weeks post-transplant were analyzed. H&E staining shows that uninfected BMT lungs 
did not display the pathological features found in latently infected BMT lungs, and 
Trichrome staining revealed no abnormal collagen deposition (Figure 3.11), suggesting 
that the pathology was virus-induced and not the result of irradiation-induced lung 
damage. 
 
To determine whether virus-induced pneumonitis observed in BMT lungs during 
virus latency was persistent or a transient response to virus latency, BMT and control 
mice were infected with 5x10
4
 pfu γHV-68. At 7 weeks post-infection, lungs were 
harvested for histology. Lung sections stained with H&E and Trichrome reveal a 
persistence of the pneumonitis phenotype and increased histology score, even 7 weeks-
post infection (Figure 3.12). 
Figure 3.11 Uninfected BMT lungs do not display pathological features observed in 
latently-infected BMT lungs. Lungs from uninfected BMT mice were harvested at 8 
weeks post-BMT, and sections were stained with H&E and Trichrome (100x 





Figure 3.12 Pneumonitis and fibrosis in BMT mice persist even 7 weeks 
post-infection. Lungs from BMT and control mice, infected with 5x10
4
 
pfu γHV-68, were harvested for histology at d49 post-infection. A. H&E 
and Trichrome-stained lung sections from BMT and control mice 49 days 
post-infection (100x magnification). B. Lung sections from BMT and 
control mice at d49 post-infection were analyzed in a blinded fashion by a 
pathologist and scored on the basis of the presence and severity of 




BMT mice have increased infiltration of inflammatory cells in the alveolar space during 
latent γHV-68 infection 
To characterize the cells present in the alveolar space at d21 post-infection, BAL 
was performed on BMT and control mice and total cells were counted. There was a 
significant increase in total cell numbers harvested from BMT lungs compared to control 
(Figure 3.13A). BAL cells from control mice were largely monocytes/ macrophages, as 
determined by differential counting. However, BMT BAL cells included an influx of 
lymphocytes and neutrophils (Figure 3.13B).  
 
Figure 3.13 BMT mice have increased infiltration of lymphocytes and 
neutrophils in the alveolar space during latent γHV-68 infection. At d21 post-
infection with 5x10
4
 pfu γHV-68, cells were harvested from the alveolar space 
of BMT and control mice using BAL. A. BMT mice have a significant 
increase in total numbers of cells harvested by BAL compared to control 
(p=0.0029, n=5 mice per group; representative of 3 independent 
experiments). B. BMT mice have increased percentages of lymphocytes and 
neutrophils in the alveolar space, as determined by differential counting (n=5 




To characterize lymphocyte populations in the alveolar space, BAL cells were 
analyzed by flow cytometry. BMT mice had significant increases in numbers of both 
CD4 and CD8 cells compared to control mice, while very few B cells were present in 






Figure 3.14 BMT mice have increased T cells in the alveolar space at 
d21 post-infection. BAL cells were harvested and stained by flow 
cytometry for CD4, CD8, and CD19. Numbers of CD4 and CD8 cells 
were significantly increased in BMT mice (p=0.0166 and p=0.0074, 





Latently infected BMT mice have reduced oxygen saturation 
To understand whether pneumonitis in BMT mice led to changes in lung 
physiology, we used the MouseOx Pulse Oximeter to measure oxygen saturation in mice 
at d21 post-infection. We hypothesized that the increased numbers of inflammatory cells 
and the presence of fibrotic lung tissue in the BMT setting would result in reduced 
pulmonary function. We found a significant decrease in oxygen saturation in BMT mice 
compared to control at d21 post-infection with γHV-68 (Figure 3.15A). However, there 
was no difference in oxygen saturation between these groups prior to infection (Figure 
3.15B).  These data indicate that latent gammaherpesvirus infection in BMT mice leads 
to reduced oxygen saturation.  
 
 
Figure 3.15 Oxygen saturation is reduced in BMT mice during latent γHV-68 infection. 
Oxygen saturation was measured in BMT and control mice using a MouseOx Pulse 
Oximeter at d21 post-infection with 5x10
4 
pfu γHV-68 (A) and at 5 weeks-post transplant 
(uninfected, B). A. BMT mice had significantly decreased oxygen saturation compared to 
control at d21 post-infection (p=0.0389, n=11 mice per group; data combined from 3 
independent experiments). B. There was no difference in oxygen saturation in control and 




Alveolar macrophages show a mixed classical and alternative activation phenotype 
As indicated in Figure 3.10A, lungs from BMT mice latently infected with γHV-
68 contained foamy alveolar macrophages. H&E staining at 400x magnification shows 
these macrophages in the BMT mouse lung (Figure 3.16A). Because alternative 
activation of macrophages has been implicated in contributing to pulmonary fibrosis in 
mice (136), we hypothesized that alveolar macrophages in our model might express 
markers of alternative activation. Alveolar macrophages from BMT and control mice at 
d21 post-infection with γHV-68 were harvested by BAL and enriched by plastic 
adherence. Expression of the classical marker iNOS and the alternative activation marker 
Arginase 1 was determined using real time RT-PCR. We found a significant increase in 
expression of both genes in BMT cells compared to control (Figure 3.16B), although 
Arginase 1 was upregulated to a greater extent than iNOS.  Interestingly, alveolar 
macrophages from BMT mice did not express IL-4 or IL-13 RNA (Appendix Figure 1), 
cytokines thought to be critical for alternative activation (135). IL-4 and IL-13 protein 
could also not be detected by ELISA in collagenase-digested lungs, and very little IL-13 
and no IL-4 RNA could be detected in cultured BAL cells, including lymphocytes in the 
BMT mice (Appendix Figure 1). Taken together, these data suggest that the alternative 





Figure 3.16 BMT alveolar macrophages are foamy and express increased iNOS and 
arginase-1. BMT and control mice were infected with 5x10
4
 pfu γHV-68 for 21 days.  A. 
H&E stained BMT lung section showing foamy alveolar macrophages (400x 
magnification). B. BAL cells from BMT and control mice were plated for 1.5h in serum-
free DMEM. Non-adherent cells were removed, and adherent cells were harvested for 
RNA. Expression of the classical activation marker, iNOS, and an alternative activation 
marker, Arginase 1 (Arg1), was significantly increased in BMT cells (p=0.0270 and 
p=0.0065, respectively) as determined by real time RT-PCR. Expression of each gene in 








BALF from BMT mice contains pro-fibrotic mediators 
Because oxidative stress has been implicated in promoting pulmonary fibrosis in 
both human (128) and murine (129)  studies, we tested levels of reactive oxygen species 
in the BALF of BMT and control mice at d21 post-infection. Levels of H2O2 and NO2- 
were significantly increased in BALF from BMT mice compared to control (Figure 
3.17A, B).  We next determined whether levels of TGFβ, a potent pro-fibrotic mediator 
(33, 121), were increased in BALF from BMT mice. At d21 post-infection, BMT mice 
had a significant increase in total TGFβ1 protein in BALF compared to control (Figure 
3.17C). Thus, these data show that BALF from BMT mice at d21 post-infection contains 







Susceptibility to infection is not explained by an early defect in inflammatory cell 
recruitment 
We were next interested in understanding the potential mechanisms contributing 
to increased lytic γHV-68 replication and pneumonitis development in our BMT model. 
We hypothesized that the increased lytic viral load observed in BMT lungs at d7 post-
infection could be attributed to defects in initial inflammatory cell recruitment or defects 
in immune cell function. To distinguish these possibilities, lungs from BMT and non-
transplanted control mice were enzymatically digested using collagenase and leukocytes 
were isolated.  Total cell numbers were determined in uninfected mice and in mice at d7 
Figure 3.17 BMT mice have increased H202, NO2-, and TGFβ1 in BALF. 
BALF was harvested from BMT and control mice at d21 post-infection 
with 5x10
4
 pfu γHV-68. The relative level of H202 (A), NO2- (B), and total 
TGFβ1 (C) were significantly increased in BMT BAL fluid compared to 
infected controls (p<0.0001, p<0.0001, and p=0.0027, respectively). (n=5 




post-infection with γHV-68.  At 5 weeks post-transplant, BMT mice had equivalent total 
cell numbers both before and at d7 post-infection when compared to non-transplanted 
control mice (Figure 3.18A).  Inflammatory cell subsets in the lung were also identified 
following infection using flow cytometry. At d7 post-infection, BMT mice had 
equivalent numbers of T cells, B cells, NK cells, NKT cells, and CD11c+I-A
B
+ APCs as 
non-transplanted control mice (Figure 3.18B). Thus, there is no evidence for a defect in 





Figure 3.18 BMT mice do not have a defect in inflammatory cell recruitment. 
A. Whole lungs from uninfected or infected (5x10
4
 pfu γHV-68 i.n., d7 post-
infection) non-transplanted control and BMT mice were digested with 
collagenase and total cells were enumerated.  Total cell numbers between 
control and BMT mice did not differ significantly in the uninfected or infected 
groups (n=4 mice per group, representative of at least 3 independent 
experiments).  B. 7 days post-infection with γHV-68 (5x10
4
 pfu, i.n.), whole 
lungs from control and BMT mice were digested in collagenase and analyzed 
by flow cytometry for expression of cell surface molecules.  Numbers of each 
subset were not statistically different between control and BMT mice (Data in 
each group is representative of at least 2 independent experiments, n= at least 




BMT APCs are effective stimulators in an MLR  
Because inflammatory cell recruitment to the lung in response to γHV-68 
infection in BMT mice was not deficient (Figure 3.18), we next explored the hypothesis 
that immune cells from BMT mice have intrinsic functional deficits. Because of the 
central importance of APCs in initiating the adaptive immune response to pathogens, we 
first determined whether APC function was altered in the BMT setting. We analyzed cell 
surface expression of MHC class II and costimulatory molecules on BMDCs from BMT 
and non-transplanted control mice. We found that BMDCs from both groups expressed 
equivalent levels of the costimulatory molecules CD80 and CD86 as well as the MHC 
class II molecule I-A
b
 on the cell surface (Figure 3.19A-C).  Accordingly, expression of 
these molecules on lung-derived CD11c+ cells purified from BMT mice (either 
uninfected or d7 post-infection) were similar or greater than levels on cells derived from 
control mice, suggesting that BMT mice do not display defects in important T cell 





   
Figure 3.19 BMT BMDCs are efficient stimulators in an MLR.  BMDCs from 
non-transplanted control or BMT mice 5 weeks post-transplant were grown 
for 7 days in GM-CSF and analyzed by flow cytometry for expression of I-A
b
 
(A), CD80 (B), and CD86 (C). BMT BMDCs expressed levels of CD80 and 
CD86 comparable to that of control cells, and slightly increased levels of I-A
b
 
(n=2 mice per group).  Similar results were found in a separate experiment 
where BMDCs were matured for 24 hours with IL-4. D. 2x10
5
 irradiated 





Balb/c splenocytes as responders. BMT BMDCs were 
able to stimulate proliferation of responder cells at least as well as control 
cells; BMT BMDCs stimulated significantly more proliferation in the 2x10
5
 
responder group (p=0.0003).  Error bars represent differences between 











Figure 3.20 Lung-derived CD11c+ I-A
B
+ APCs from uninfected 
BMT mice express increased levels of MHC class II, CD80 and 
CD86 as compared to APCs from control mice.  Lungs from BMT 
and control mice were digested with collagenase and enriched for 
CD11c-expressing cells using magnetic separation. Cells were 
stained for expression of I-A
b 
(A), CD80 (B), and CD86 (C) and 
analyzed by flow cytometry. BMT APCs expressed increased levels 







To test the ability of the BMDCs from BMT mice to function as APCs, we set up 
MLRs using irradiated BMDCs from BMT or non-transplanted control mice as 
stimulators and Balb/c splenocytes as responders (Figure 3.19D).  Our results 
demonstrated that BMDCs from BMT mice were capable of stimulating T cell 
proliferation equivalent to or even more effectively than stimulators from non-
transplanted controls. Similar results were obtained when we tested unfractionated 
Figure 3.21 Lung-derived CD11c+ I-A
B
+ APCs from infected BMT mice express 
similar levels of MHC class II, CD80 and CD86 as APCs from control mice.  
Lungs from BMT and control mice at d7 post-infection with γHV-68 were 
digested with collagenase and enriched for CD11c-expressing cells using 
magnetic separation. Cells were stained for expression of I-A
b 
(A), CD80 (B), and 
CD86 (C) and analyzed by flow cytometry. BMT APCs expressed equivalent 





splenocytes from control or BMT mice as APCs in an MLR (Figure 3.22).  These data 
suggest that APCs derived from BMT mice have the ability to function in vitro.  
 
BMT T cells are impaired in an MLR response 
We next explored the possibility that T cells from BMT mice had impaired 
function, a hypothesis supported by human HSCT patient data showing intrinsic T cell 
defects in in vitro assays (10-12). In order to assay T cell function, we set up MLRs using 
irradiated Balb/c splenocytes as stimulators and unfractionated BMT or control spleen 
cells as responders.  The BMT responder splenocytes were impaired in their proliferative 
response (Figure 3.23A) despite the fact that there were no differences in the numbers of 
CD4 cells found in the spleens of control or BMT mice. To directly compare the 
Figure 3.22 BMT splenocytes are efficient stimulators in an MLR. 2x10
5
 
irradiated splenocytes from BMT or control mice were used as 






 Balb/c splenocytes 
as responders. BMT splenocytes were able to stimulate proliferation of 
responder cells at least as well as control cells. Error bars represent 




proliferative capacity of CD4 T cells from control and BMT mice, we next isolated 
splenic CD4 cells via magnetic purification and used these cells as responders against 
irradiated Balb/c splenocytes. Similar to the results seen with unfractionated splenocytes, 
purified CD4 T cells from BMT mice displayed impaired proliferative responses in this 
allo-MLR reaction (Figure 3.23B). These data suggest that BMT T cell responses are 
impaired in vitro.  
 
BMT mice show increased levels of PGE2 in the lung  
Our laboratory has previously shown that syngeneic BMT mice overexpress PGE2 
in the lungs at 5 weeks post-BMT, leading to defects in anti-bacterial macrophage and 
neutrophil function in these mice (60). Since PGE2 has been linked to inhibition of T cell 
responses  (171), we hypothesized that increased PGE2 levels may also contribute to 
Figure 3.23 BMT cells are poor responders in an MLR. 2x10
5
 Balb/c 
irradiated splenocytes were used as stimulators in an MLR.  In panel A, 
BMT whole spleen cell responders proliferated significantly less than 
control cells.  In panel B, purified CD4 cells from BMT or control spleens 
were used as responders in a MLR.  BMT CD4 cells responded 




 responders were 





impaired T cell responses and, therefore, impaired anti-viral immunity. We found that 
PGE2 was significantly increased in the lungs of BMT mice at d7 post-infection with 
5x10
4
 pfu γHV-68 (Figure 3.24A). However, treatment of mice with indomethacin (a 
cyclooxygenase inhibitor which blocks PGE2 synthesis) during the infection did not 
improve control of viral replication, despite reductions in PGE2 levels (Figure 3.24B,C). 
These data indicate that although PGE2 is overproduced in the lungs of BMT mice, it 
does not limit anti-viral immunity to lytic γHV-68 infection. However, we did not 
evaluate the role of PGE2 at other time points post-infection or on the development of 








Figure 3.24 Overproduction of PGE2 in the lung post-BMT does not explain 
impaired anti-viral immunity. BMT and control mice were infected i.n. with 
5x10
4
 pfu γHV-68. A. Whole lungs were harvested at d7 post-infection and 
assayed for PGE2 by ELISA. Lungs of BMT mice produced significantly more 
PGE2 than non-transplanted controls (p=0.0230, n=5 mice per group, 
representative of 2 independent experiments). B. During each day of the 
infection, mice were given a i.p. injection containing indomethacin (1.2 mg/kg) 
or DMSO as a vehicle control. At d7 post-infection, left lungs were harvested 
for RNA and expression of lytic viral genes was determined using real time RT-
PCR.  Expression of the viral capsid gene (B) and the viral DNA polymerase (C) 
was significantly increased in both the indomethacin-treated and vehicle-treated 
BMT mice compared to non-transplanted controls. Indomethacin treatment 
effectively reduced PGE2 levels in the BMT mice from 126.054 ng/mL to 7.779 
ng/mL, as determined at day 7 post-infection by ELISA of right lungs (n=8-9 




Altered T cell differentiation in BMT lungs 
Proper cytokine production during lytic γHV-68 infection is required for efficient 
control of viral replication. Specifically, IFNγ production by CD4 cells is critical (77-79). 
Based on this knowledge, we hypothesized that T cell differentiation may be altered in 
the BMT setting in response to lytic γHV-68 infection in the lung. To test this hypothesis, 
lungs from BMT and control mice were harvested at d7 post-infection with γHV-68. 
Lungs were digested using collagenase, and expression of IFNγ, IL-17a, and Foxp3 was 
measured using intracellular staining and flow cytometry, as indicators of Th1, Th17, and 
Tregs in the lung. We find that at d7 post-infection, BMT mice have decreased numbers 
of Th1 cells, increased numbers of Th17 cells, and increased numbers of Foxp3+ Tregs 
when compared to control mice (Figure 3.25). Furthermore, numbers of Tregs were 







Figure 3.25 Altered T cell differentiation in lungs of BMT mice in response to γHV-
68. Lungs from BMT and control mice, uninfected or infected (5x10
4
 pfu γHV-68, 
i.n., d7), were digested with collagenase and analyzed by flow cytometry. A. Lungs 
from uninfected BMT mice had significantly more CD4+Foxp3+ cells than non-
transplanted controls (p=0.0002, n=4 mice per group, representative of 2 
independent experiments). At d7 post-infection, BMT lungs had significantly 
higher numbers of CD4+Foxp3+ cells than non-transplant controls (p=0.0104, n=4 
mice per group, representative of at least 6 independent experiments) B and C. 
Lung cells were stimulated with PMA and ionomycin and analyzed by flow 
cytometry using antibodies against CD4, IFNγ and IL-17a. B. BMT mice showed a 
significant decrease in numbers of CD4+IFNγ+ cells compared to non-transplanted 
control mice (p=0.0207). C. BMT lungs had a significant increase (p=0.0002) in 
numbers of CD4+IL-17a+ cells compared to non-transplant controls (n=5 per 




Lungs from BMT mice overexpress TGFβ 
TGFβ has been reported to promote Treg and Th17 differentiation, as well as limit 
Th1 differentiation. Thus, we hypothesized that TGFβ may be overexpressed in the lungs 
of BMT mice in our model. We found that lungs of uninfected BMT mice have 
significantly higher levels of TGFβ1 compared to non-transplanted control mice (Figure 
3.26). We hypothesized that the increased levels of TGFβ1 may be attributed in part to 
epithelial cell damage as a result of the TBI conditioning regimen (33).  To determine 
whether alveolar epithelial cells (AECs) were a significant source of TGFβ1 post-BMT, 
we purified AECs from non-transplanted control and BMT mice at week 5 post-
transplant.  AECs were then cultured and supernatants were analyzed for total TGFβ1 
levels by ELISA.  Figure 3.26B demonstrates that AECs from BMT mice are a source of 
TGFβ1 even 5 weeks post-transplant. In order to determine if radiation dose affected 
TGFβ1 levels in the lung, transplants were performed following increasing doses of 





Depletion of Tregs from BMT mice does not restore anti-viral immunity 
 We hypothesized that the elevated number of Tregs in the lungs of BMT mice 
was suppressing anti-viral immunity. To test this hypothesis, BMT mice were treated 
with either anti-CD25 or isotype control at 4 weeks post-BMT. At 5 weeks post-BMT, (1 
week following antibody treatment), mice were infected i.n. with 5x10
4
 pfu γHV-68. Left 
lungs were harvested for RNA, and expression of the lytic viral capsid gene gB and viral 
DNA polymerase was determined by real time RT-PCR. There was no difference in viral 
gene expression between BMT mice treated with isotype and those treated with anti-
CD25. Both BMT groups showed a significant increase in viral gene expression 
compared to isotype-treated non-transplant controls (Figure 3.27). Flow cytometry for 
lung CD4+Foxp3+ cells showed that Treg numbers in anti-CD25-treated BMT mice (1 
Figure 3.26 BMT mice overexpress TGFβ1. A. Lungs of uninfected BMT mice 
produced significantly more TGFβ1 than control, as determined by ELISA 
(p=0.0015, n=5 mice per group, representative of 2 independent experiments). 
B. Alveolar epithelial cells (AECs) were isolated from lungs of uninfected BMT 
and control mice and were assayed for production of TGFβ1 by ELISA 
following 24 hour culture in serum-free media. BMT AECs produced 
significantly more TGFβ1 than control AECs (p<0.0001, n=6 per group, 




week following antibody treatment) were similar to those seen in isotype-treated, non-
transplant control mice on the day of infection (Figure 3.28). Similar results were found 
at d7 post-infection, showing that Treg depletion persisted throughout the infection 
period (Figure 3.28).  
 These data indicate that increased numbers of Tregs in the BMT lung is not 
sufficient to limit antiviral immunity to γHV-68 replication. To test whether Tregs 
purified from the BMT setting were functional suppressor cells, Tregs were isolated from 
BMT and control spleens and used as suppressors in an in vitro T cell proliferation assay. 
BMT Tregs were capable of suppressing T cell proliferation as well as Tregs isolated 











Figure 3.27 Depletion of Tregs does not restore anti-viral immunity in 
BMT mice. BMT mice were treated with a single dose of either anti-
CD25 or isotype control antibody at 4 weeks post-BMT.  At 5 weeks 
post-BMT (1 week following antibody treatment), mice were infected 
with 5x10
4
 pfu γHV-68. Left lungs were harvested for RNA at d7 
post-infection, and expression of lytic viral genes was determined by 
real time RT-PCR. Expression of both the capsid gene gB and viral 
DNA polymerase was significantly increased in BMT mice treated 
with either isotype or anti-CD25 compared to isotype-control treated, 





Figure 3.28 Anti-CD25 treatment reduces BMT lung Treg numbers to 
control levels. BMT mice were treated i.p. with a single dose of either 
anti-CD25 or isotype control antibody at 4 weeks post-BMT. At 5 weeks 
post-BMT (1 week following antibody treatment), lungs were harvested 
for flow cytometry or mice were infected with 5x10
4
 pfu γHV-68. A. 
Numbers of CD4+Foxp3+ cells in uninfected lungs were significantly 
increased in the isotype-treated BMT mice but were at control levels in 
anti-CD25-treated mice (n=4-5 per group). B. Numbers of CD4+Foxp3+ 
cells in right lungs remained decreased in anti-CD25 treated mice at d7  





IL-17a does not limit anti-viral immunity in the BMT setting  
We reported increased numbers of IL-17a-expressing CD4 cells in the BMT 
mouse lung in response to γHV-68 infection (Figure 3.25). There are limited data 
regarding the role of IL-17a in viral infection; some reports indicate that IL-17a plays a 
protective role, while others indicate that IL-17a limits anti-viral responses, depending on 
the specific virus (172). There are no reports to date on the role of IL-17a in γHV-68 
infection. To determine whether IL-17a limits immunity to γHV-68 and whether 
increased Th17 cells is the mechanism for impaired immunity to γHV-68, we set up 
infections using IL-17KO mice. We first compared lytic viral replication of γHV-68 
infection in non-transplanted wild type and IL-17KO mice. We infected mice i.n. with 
5x10
4
 pfu γHV-68 and harvested lungs for RNA at d7 post-infection. We found no 
difference by real time RT-PCR in expression of the lytic viral genes gB and DNA 
polymerase (Figure 3.30). We next set up transplants using wild type donors or IL-17KO 
Figure 3.29 BMT Tregs are functional suppressors in vitro. 
CD4+CD25+ Tregs and CD4+ responder cells were isolated from 
spleens using magnetic bead separation. 1x10
5
 CD4+ BMT responders 
were cultured for 3 days with anti-CD3 and syngeneic accessory cells (T 
depleted splenocytes) +/- 5x10
4
 BMT or control Tregs. After 3 days, 
3
H 
was added to cultures and plates were harvested for scintillation 




donors; the repopulated immune system in the IL-17KO BMT mice would be unable to 
produce IL-17a. Similar to the non-transplant setting, we found no difference in 
expression of lytic viral genes in the lung at d7 post-infection between wild type BMT 
and IL-17KO BMT mice. Taken together, these data suggest that overproduction of IL-
17a post-transplant does not limit anti-viral immunity to lytic γHV-68 infection in the 
lung, at least at d7 post-infection.   
 
Figure 3.30 IL-17a does not play a role in controlling lytic γHV-68 replication 
in the lung. Wild type and IL-17KO non-transplanted mice (A. and B.) or wild 
type BMT and IL-17KO BMT mice (C. and D.) were infected with 5x10
4
 pfu 
γHV-68. At d7 post-infection, lungs were harvested for RNA, and expression of 
the viral capsid gene gB and the viral DNA polymerase was measured using real 
time RT-PCR. There was no significant difference in expression of either gene 
in non-transplant and transplant settings. (A. and B. n=9 wild type, 11 IL-17KO; 




Reduced IL-12 production by BMT dendritic cells is not sufficient to alter Th1 
differentiation in vitro 
We next determined whether the diminished Th1 response in BMT lungs in 
response to γHV-68 infection (Figure 3.25B) was due to altered cytokine production by 
APCs. We first looked for IL-12 production by control and BMT APCs, as IL-12 is a 
critical cytokine for Th1 differentiation. We found that at baseline and upon TLR 
stimulation, BMDCs from BMT mice express significantly less IL-12p35 transcript 
compared to control (Figure 3.31A). This correlated with reduced IL-12p70 protein 
production upon TLR stimulation in BMT BMDCs (Figure 3.31B). Additionally, lung-
derived CD11c cells from uninfected BMT mice express significantly less IL-12p35 
compared to control (Figure 3.32A). However, lung CD11c cells derived from BMT 
lungs at d7 post-infection with γHV-68 express equivalent IL-12p35 as control mice 
(Figure 3.32B.) 
To test whether reduced IL-12 production by BMT dendritic cells was sufficient 
to skew T cell responses away from Th1, we set up co-cultures with BMT and control 
BMDCs and T cells. Control or BMT BMDCs were incubated with OVA protein with or 
without LPS and then were cultured for 48h with OVA-specific OT-II splenic CD4 cells. 
ELISA on cell supernatants showed equivalent IFNγ production from T cells stimulated 
with BMT or control BMDCs (Figure 3.33). These data, in addition to the data showing 
that IL-12 production was not reduced in BMT mice at d7 post-infection (Figure 3.32B), 
suggest that reduced IL-12 production by BMT dendritic cells may not be sufficient to 





Figure 3.32 Lung-derived CD11c+ cells have reduced IL-12p35 when harvested from 
uninfected, but not infected BMT mice. CD11c+ cells were enriched by magnetic 
separation from BMT or control collagenase-digested lungs, either uninfected or at d7 
post-infection with 5x10
4
 pfu γHV-68. 1x10
6
 cells/ mL were cultured for 24h with or 
without LPS at 1 µg/mL. Cells were then harvested for RNA, and expression of IL-12p35 
was determined using real time RT-PCR. A. Lung CD11c cells from uninfected BMT 
mice expressed decreased IL-12p35 compared to control when treated with LPS 
(p=0.0454, n=3 per group). B. Lung CD11c cells from control and BMT mice at d7 post-
infection expressed similar levels of IL-12p35 in the presence or absence of LPS (n=6 
per group).  
 
Figure 3.31 Reduced IL-12 production by BMT BMDCs. BMT and control 
BMDCs were cultured (1x10
6
 cells/mL) with or without LPS (1 µg/mL) for 24h. 
Cells were harvested for RNA, and supernatants were harvested for ELISA. A. 
Expression of IL-12p35 in BMT cells was significantly decreased with and 
without LPS treatment, as determined by real time RT-PCR. B. ELISA on cell 
supernatants showed no difference in IL-12p70 production by unstimulated BMT 
and control cells; there was a significant decrease in IL-12p70 production in LPS-
treated BMT cultures compared to control (n=6 per group, representative of 2 






BMT T cells express reduced Tbet and increased TGFβ at baseline 
Because the reduced IL-12 expression in BMT BMDCs was not sufficient to skew 
away from Th1 differentiation in vitro, we hypothesized that T cells from BMT mice had 
intrinsic alterations which may skew them away from Th1 differentiation. This 
hypothesis was supported by our data showing that BMT T cells had intrinsic defects in 
Figure 3.33 BMT and Control BMDCs induce similar IFNγ production 
in vitro. 8x10
4
 BMT or Control BMDCs were incubated with whole 
OVA protein (1 mg/mL used at 1:100 in culture) for 2h with (B) or 
without (A) LPS at 1 µg/mL. Media was removed and replaced with 
fresh media plus 8x10
5
 magnet-purified OVA-specific splenic OT-II 
CD4 cells from a naïve mouse. Supernatants were harvested 48h later 
and assayed for IFNγ by ELISA. (A. n=6 per group; representative of 2 




proliferation in vitro (Figure 3.23). We found that T cells derived from BMT mice 
expressed decreased levels of the Th1 transcription factor Tbet at baseline, without any 
stimulation (Figure 3.34). Additionally, because TGFβ is known to limit Th1 
differentiation by inhibiting Tbet (17), we hypothesized that T cells from BMT mice may 
overexpress TGFβ. Indeed, we find that both CD4 and CD8 cells from BMT mice 
produce increased TGFβ at baseline.  
 
 
Figure 3.34 BMT T cells express decreased Tbet and increased TGFβ at 
baseline. A. Tbet expression in BMT splenic T cells was significantly reduced 
compared to control as determined by real time RT-PCR. B. Splenic CD4 
cells from BMT mice produced increased TGFβ compared to control by 
ELISA (n=6 control, 5 BMT; representative of 2 independent experiments). 
C. Splenic CD8 cells from BMT mice produced increased TGFβ compared to 
control by ELISA (n=3 per group; representative of 2 independent 




Mice transplanted with T cell-DN-TGFβRII bone marrow have restored immunity to lytic 
γHV-68 
 In order to determine whether the increased levels of TGFβ1 in the lung 
contributed to impaired anti-viral T cell responses in the BMT mice, we performed 
transplants using bone marrow from mice which express a dominant negative form of the 
TGFβ Receptor II under control of the CD4 promoter (T cell-DN-TGFβRII) (104).  This 
particular promoter configuration is expressed in both CD4 and CD8 cells.  This 
approach ensures that donor-derived T cells (CD4 and CD8) will be unresponsive to 
TGFβ1.  Five weeks post-BMT, total cell numbers within the lung were not different in 
control, wild type syngeneic BMT and T cell-DN-TGFβRII BMT mice. At this time 
point, mice were infected i.n. with 5x10
4
 pfu γHV-68. At d7 post-infection, lungs from T 
cell-DN-TGFβRII BMT, wild type BMT and non-transplant control mice were analyzed 
for expression of lytic viral genes by real time RT-PCR. Our data demonstrate that T cell-
DN-TGFβRII BMT mice (in which the donor-derived T cells are unresponsive to 
TGFβ1) have restored immunity to γHV-68, as expression of the viral capsid gene 
(Figure 3.35A) and viral DNA polymerase (Figure 3.35B) were not significantly different 





Figure 3.35 Transplanting mice with T cell-DN-TGFβRII bone marrow 
restores immunity to γHV-68. Control mice and mice transplanted with 
syngeneic wild type or T cell-DN-TGFβRII bone marrow were infected i.n. 
with 5x10
4
 pfu γHV-68 and analyzed at day 7 post-infection.  A. Expression 
of the viral capsid gene gB was significantly increased in the lungs of wild 
type BMT mice compared to non-transplanted control mice; however, there 
was no significant difference between control and T cell-DN-TGFβRII BMT 
groups. B. Expression of viral DNA polymerase was significantly increased 
in wild type BMT lungs when compared to non-transplanted control mice. 
There was no significant difference between the control and T cell-DN-
TGFβRII BMT mice (n=4-5 mice per group; data representative of 2 




We next determined whether T cell-DN-TGFβRII BMT mice would have restored 
numbers of Th1 cells in the lung in response to γHV-68. T cell-DN-TGFβRII BMT, wild 
type BMT, and non-transplant control mice were infected i.n. with 5x10
4 
pfu γHV-68. At 
d7 post-infection, lungs were digested in collagenase and analyzed by flow cytometry for 
expression of CD4 and IFNγ. Consistent with our earlier experiments (Figure 3.25), wild 
type BMT mice had significantly reduced numbers of CD4+IFNγ+ cells in the lung 
compared to non-transplant control. In contrast, T cell-DN-TGFβRII BMT mice had 
restored numbers of Th1 cells (Figure 3.36A). We next enriched T cells from the spleens 
of uninfected wild type BMT and T cell-DN-TGFβRII BMT mice and stimulated them 
with PMA and ionomycin in vitro. T cells from T cell-DN-TGFβRII BMT mice produced 
increased levels of IFNγ and lower levels of IL-17a suggesting that the T cell cytokine 






Figure 3.36 T cells from T cell-DN-TGFβRII BMT mice express higher 
amounts of IFNγ and lesser amounts of IL-17a. A. Right lungs from control, 
wild type BMT, and T cell-DN-TGFβRII BMT mice were harvested d7 post-
infection with 5x10
4
 pfu γHV-68, digested in collagenase and analyzed using 
flow cytometry (n=5 per group). B. and C. Splenocytes from syngeneic 
BMT and T cell-DN-TGFβRII BMT mice were depleted of CD19-
expressing cells via magnetic separation. Cells were then cultured with PMA 
and ionomycin for 24 hours. Supernatants were harvested and assayed for 
expression of IFNγ and IL-17a by ELISA. B. Wild type BMT cells expressed 
significantly less IFNγ than T cell-DN-TGFβRII BMT cells (p=0.0004, n=5 
per group). C. Syngeneic BMT cells expressed significantly more IL-17a 




We next analyzed lungs for the presence of Tregs in T cell-DN-TGFβRII BMT, 
wild type syngeneic BMT and non-transplanted control mice. Consistent with our 
previous observations (Figure 3.25), both groups of BMT mice showed elevated numbers 
of Tregs (Figure 3.37A). We also analyzed the lungs at d7 post-infection for Th17 cells. 
Consistent with the data shown in Figure 3.25, wild type BMT mice had increased 
numbers of Th17 cells compared to control. T cell-DN-TGFβRII BMT mice also had 
increased Th17 cells (Figure 3.37B). These data show that the T cell-DN-TGFβRII BMT 
mice are able to effectively control lytic viral replication despite the continued presence 
of increased numbers of Tregs and Th17 cells in the lungs post-BMT, further confirming 
the notion that Tregs and Th17 cells do not impair anti-viral immunity in the BMT setting 








Figure 3.37 T cell-DN-TGFβRII BMT mice have increased Tregs and Th17 cells 
at d7 post-infection with γHV-68. Right lungs from non-transplant control, wild 
type BMT, and T cell-DN-TGFβRII BMT mice were harvested at d7 post-
infection with 5x10
4
 pfu γHV-68, digested in collagenase and analyzed using 
flow cytometry. A. Both wild type and T cell-DN-TGFβRII BMT mice had 
significantly higher numbers of Tregs compared to non-transplanted controls 
(n=5 mice per group; data representative of 2 independent experiments). B. 
Both wild type and T cell-DN-TGFβRII BMT mice had significantly higher 





Blocking TGFβ signaling in innate immune cells in the lung does not restore lytic viral 
load  
Because TGFβ is a pleiotropic cytokine with immunosuppressive effects on 
multiple cell types (Table 1.1), we next determined whether overexpression of TGFβ 
post-transplant suppressed innate immune responses to lytic γHV-68 infection in the 
lung. We set up transplants using a CD11c-DN-TGFβRII donor mouse (114), expressing 
the DN-TGFβRII transgene under the CD11c promoter. In the lung, TGFβ signaling 
would be blocked in CD11c-expressing cells, including dendritic cells, natural killer 
cells, and likely lung macrophages. We infected non-transplant control, wild type BMT, 
and CD11c-DN-TGFβRII BMT mice with 5x10
4
 pfu γHV-68. At d7 post-infection, lungs 
were harvested for RNA and expression of lytic viral genes was determined using real 
time RT-PCR. We found that CD11c-DN-TGFβRII BMT mice express increased levels 
of lytic viral genes, similar to wild type BMT mice, suggesting that TGFβ signaling in 
CD11c-expressing cells does not contribute to the impaired acute anti-viral immune 






Figure 3.38 CD11c-DN-TGFβRII BMT mice have increased lytic viral 
gene expression. CD11c-DN-TGFβRII BMT mice showed a 
significant increase in viral capsid gene (A) and viral DNA polymerase 
(B) expression compared to non-transplant control mice. There was no 
significant difference between wild type BMT and CD11c-DN-
TGFβRII BMT. (n=4 control, 5 wild type BMT, and 5 CD11c-DN-
TGFβRII BMT). Expression of both genes is not significantly different 




Blocking TGFβ signaling significantly improves pneumonitis and fibrosis in BMT mice 
Because T cell-DN-TGFβRII BMT mice had restored control of lytic viral 
replication, we hypothesized that this would correlate with prevention of severe 
pneumonitis and fibrosis. We infected mice with 5x10
4
 pfu γHV-68 and harvested lungs 
for histology at d21 post-infection. We found a drastic reduction in pneumonitis, fibrosis, 
and overall histology score in BMT mice transplanted with T cell-DN-TGFβRII bone 
marrow (Figure 3.39). However, BMT mice transplanted with CD11c-DN-TGFβRII bone 
marrow had only a modest reduction in histology score (Figure 3.39). Taken together, 
these data suggest that TGFβ affects multiple cell types in promoting pneumonitis and 
fibrosis in response to γHV-68 in the BMT setting, but the most dramatic effects appear 






Figure 3.39 Transplanting mice with T cell-DN-TGFβRII or CD11c-
DN-TGFβRII bone marrow reduces presence of pneumonitis and 
fibrosis during latent γHV-68 infection.  BMT mice transplanted with 
T cell-DN-TGFβRII or CD11c-DN-TGFβRII bone marrow were 
infected with 5x10
4
 pfu γHV-68. Lungs were harvested at d21 post-
infection for histology and stained for H&E and Masson’s 
Trichrome. A. H&E and Trichrome stained lung sections (100x 
magnification). B. Lung sections were scored in a blinded fashion by 
a pathologist on the basis of presence and severity of pathological 
features (n=5 T cell-DN-TGFβRII and 4 CD11c-DN-TGFβRII BMT 





Severity of pneumonitis in BMT mice depends on initial viral dose 
 We next set up experiments to more directly test the hypothesis that uncontrolled 
lytic replication may contribute to the development of pneumonitis and fibrosis in the 
BMT setting during virus latency. We show in Figure 3.3 that BMT mice have an 
increasing inability to control lytic γHV-68 infection with higher viral challenge. Thus, 






 pfu γHV-68 and harvested lungs for 
histology at d21 post-infection. We found that 4 out of the 5 BMT mice infected with 
3x10
5
 pfu γHV-68 succumbed to infection around d14; however, we do not know 
whether this is due severely high lytic viral titers or due to pneumonitis. When lungs from 




 pfu were compared, we observed that 
pneumonitis was more severe, involving a greater area of the lung, in the BMT mice 
infected with higher viral inoculum (Figure 3.40). Thus, these data support a model 









Figure 3.40 BMT mice have more severe pneumonitis and fibrosis with 





γHV-68, and lungs were harvested for histology at d21. Lung sections were 
stained with H&E and Trichrome (100x magnification, representative of 




Chapter 4  
Discussion 
Summary of Results 
In these studies we have established a murine syngeneic BMT model wherein 
transplanted mice have reduced ability to control lytic γHV-68 replication and 
subsequently develop pneumonitis and lung fibrosis during virus latency. In our model, 
BMT mice are challenged with γHV-68 at 5 weeks post-transplant, a time point when 
immune cell numbers in the lung are reconstituted. Following virus challenge, BMT mice 
have increased viral load at d7 post-infection with γHV-68, as determined by viral gene 
expression in the lungs, viral plaque assay, and viral immunohistochemistry. We find that 
increased viral gene expression in the lung persists at d14 post-infection.  
By d21 post-infection, however, when γHV-68 is latent in the lungs, BMT and 
non-transplanted control mice have equivalent viral load. Histological analysis reveals 
that during virus latency, BMT mice develop severe pneumonitis characterized by foamy 
alveolar macrophages, increased levels of H2O2 and NO2-, and increased infiltration of 
neutrophils and T cells in the alveolar space. Additionally, Trichrome staining and real 
time RT-PCR for collagen expression indicates development of lung fibrosis in BMT, but 
not control lungs, during virus latency. Correspondingly, BMT mice have reduced 




phenotype observed during virus latency is virus-induced, as uninfected BMT mice do 
not develop pneumonitis, fibrosis, or reduced oxygen saturation.  
We have also established that BMT mice are able to recruit inflammatory cells to 
the lung in response to lytic γHV-68 infection. Additionally, BMT APCs grown from 
bone marrow in vitro or isolated from the uninfected or infected lungs have expression of 
MHC Class II and costimulatory molecules equivalent to or greater than levels seen on 
control cells. Accordingly, BMT dendritic cells and splenocytes are efficient stimulators 
in an MLR. However, we find that BMT T cells are poor responders in an MLR.  
Lungs from BMT mice overexpress TGFβ at baseline, and at d7 post-infection 
with γHV-68, there is a significant decrease in Th1 and increase in Th17 cells in the 
lungs of BMT mice compared to control. Treg numbers are increased in the BMT lung 
both prior to infection and at d7 post-infection. Treating mice during infection with a 
cyclooxygenase inhibitor which blocks PGE2 synthesis does not restore anti-viral 
immunity. Additionally, depletion of Tregs or transplanting mice with IL-17KO bone 
marrow also does not alter the increased viral load in BMT mice.  
Additionally, we have found that although BMT dendritic cells produce decreased 
levels of IL-12, we that this is not sufficient to skew away from a Th1 response in vitro. 
Rather, BMT T cells express decreased Tbet and increased TGFβ at baseline. We set up 
experiments using BMT mice transplanted with transgenic bone marrow expressing DN-
TGFβRII in T cells or under the CD11c promoter, blocking TGFβ signaling in CD4 and 
CD8 cells or CD11c-expressing cells, respectively. T cell-DN-TGFβRII BMT mice have 




from the pneumonitis phenotype. However, CD11c-DN-TGFβRII BMT mice show 
increased susceptibility to lytic infection, similar to wild type BMT, and are only 
moderately protected from pneumonitis. Furthermore, wild type BMT mice infected with 
lower amounts of virus have less severe pneumonitis. Taken together, our data support a 
model wherein overexpression of TGFβ post-BMT limits Th1 responses to acute γHV-68 
infection, promoting higher initial viral titers and lung damage, leading to the 
development of pneumonitis and fibrosis in these mice.  
Discussion: γHV-68 infection and pneumonitis in murine BMT 
Studies in our model show that at 5 weeks post-transplant, syngeneic BMT mice 
are unable to control acute lytic replication as well as non-transplanted control mice 
(Figure 3.1). This corresponds with clinical reports showing opportunistic infections 
occurring late post-transplant in autologous HSCT recipients (6, 7). We find that the 
magnitude of the host defense defect is influenced both by the dose of irradiation used for 
conditioning and also by the dose of virus used for infection. Significant increases in viral 
load occurred in mice conditioned with 1350 rads of TBI (Figure 3.2). In our hands, 
conditioning with 1350 rads results in approximately 95% reconstitution within the 
spleen, 82% reconstitution of alveolar macrophages, and 93% lung lymphocytes (161). In 
contrast, 800 rads permitted approximately 88% reconstitution in the spleen, but only 
36% reconstitution of donor-derived alveolar macrophages (170). Thus, increased 
susceptibility noted in the mice conditioned with 1350 rads may be related to increased 
myeloablation and enhanced donor cell reconstitution or increased radiation toxicity. The 
former seems more likely, as T cells from BMT mice have decreased expression of Tbet 




elevations in viral replication (as noted by expression of a viral capsid protein) at all 
doses of virus tested, but the magnitude of the difference between control and BMT mice 
was increased with higher viral inoculums (Figure 3.3). This suggests that the immune 
response in BMT mice is overwhelmed by increasing pathogenic challenge.  
We report that BMT and control mice have equivalent latent viral loads at d21 
post-infection (Figure 3.5), despite increased lytic virus in BMT mice. Our results are 
consistent with previous studies showing that lytic virus titers do not correlate with latent 
levels of γHV-68 (70, 71).  We hypothesize that much of the lytic replication at day 7 
may be occurring in cell types that do not survive or remain resident in the lung by day 
21.  Despite having no difference in latent viral load, we find that BMT mice develop 
severe, persistent pneumonitis and fibrosis during latent γHV-68 infection (Figure 3.6). It 
is important to note that in our model, we find that the pneumonitis phenotype is virus-
induced. Uninfected BMT mice show no signs of pneumonitis or fibrosis at 2 months 
post-transplant (Figure 3.11). Although irradiated C57BL/6 mice can develop irradiation-
induced fibrosis, this does not occur until 20-30 weeks post-irradiation, long after the 8 
week time point used in our studies (173).  The development of pneumonitis in our model 
does not occur until lytic replication has largely subsided in the lung. In this respect, our 
model mimics results of a prospective study of pediatric allogeneic HSCT recipients 
showing that early respiratory virus infection post-transplant was correlated with later 
development of IPS and bronchiolitis obliterans. Importantly, patients had recovered 
from their initial respiratory symptoms prior to development of later respiratory 
symptoms associated with IPS or bronchiolitis obliterans, which are in part clinically 




viral infection can lead to pneumonitis and lung injury at later time points, even after 
resolution of the initial lytic insult. 
The concept that level of virus load does not correlate with lung pathology is in 
accordance with a study of HSV-1 pneumonitis where viral loads were decreased in 
allogeneic BMT mice with GVHD compared to non-GVHD allogeneic mice. In that 
study, lung pathology was more severe in mice that had developed GVHD, despite 
decreased viral loads (123). Similarly, another study found that viral titers were not 
predictive of interstitial pneumonitis development upon MCMV infection in GVHD mice 
versus controls (174). However, unlike our model, these studies both looked at viral titers 
early post-infection and involved the complication of GVHD.  
In accordance with the severe inflammatory and fibrotic phenotype in BMT mice 
at d21 post-infection with γHV-68, our data show that these mice also have reduced 
oxygen saturation (Figure 3.15). It is important to highlight that this reduced oxygen 
saturation measures values at rest and might be even more substantial if mice were 
exercised. The reduced oxygen saturation in our BMT mice correlates with reports of 
abnormal pulmonary function tests which persist long-term in HSCT recipients (31). Our 
data suggest that unresolved inflammation from a previous infection may contribute to 
long-term reduced pulmonary function in HSCT recipients.  
In our model, we find infiltration of inflammatory cells including neutrophils and 
lymphocytes in the alveolar space during latent γHV-68 infection in BMT mice (Figure 
3.13). We find that the largest lymphocyte population present in the alveolar space in 




during γHV-68 latency (175). We speculate that the infiltration of these cells into the 
alveolar space may be indicative of unresolved inflammation due to the initial virus 
infection, as a preliminary data indicate that a percentage of CD8 cells are specific for a 
viral epitope. The resident cell population in the alveolar space of uninfected BMT and 
control mice consists almost exclusively of monocytes/macrophages (data not shown). 
We also note the presence of large, foamy alveolar macrophages in BMT lungs (Figure 
3.16) during latent γHV-68 infection. When the alveolar macrophage population was 
enriched from BMT mice at d21 post-infection, we found that these cells express the 
classical activation marker iNOS, an enzyme which catalyzes production of nitric oxide, 
as well as the alternative activation marker Arginase 1, an enzyme which promotes 
fibroblast proliferation and collagen production (Figure 3.16). Of note, the induction of 
Arginase 1 is greater than the induction of iNOS on a population basis, but both are 
clearly induced. Classically activated macrophages are thought to promote inflammation 
while alternatively activated macrophages are associated with wound repair (134, 135). 
The dichotomy of function between these macrophage subsets correlates well with the 
inflammatory and fibrotic phenotypes in the BMT lung during γHV-68 latency. Future 
studies will determine whether these markers are expressed on the same macrophages, or 
whether there are two distinct populations present in the alveolar space. 
Alternatively activated macrophages have been implicated in promoting 
pulmonary fibrosis during chronic γHV-68 infection in IFNγRKO mice. In these studies, 
the appearance of these macrophages was attributed to the Th2 environment and 
expression of IL-13 (136) in these Th2-biased mice. Interestingly, in our model, we find 




macrophages, or in whole lung homogenates (Appendix Figure 1). However, we report a 
significant decrease in numbers of IFNγ-producing CD4 cells in the lungs of BMT mice 
during lytic γHV-68 infection  at d7 post-infection (Figure 3.25), suggesting that the 
development of Arginase 1-expressing alveolar macrophages may occur in the absence of 
an overwhelming Th1 response, not simply to the presence of a Th2 response. It is also 
possible that increased TGFβ (Figure 3.26) or increased IL-10 noted at d21 post-infection 
(Appendix Figure 4) may contribute to the alternative activation phenotype (176). 
However, both CD11c-DN-TGFβRII BMT mice and transplants using IL-10KO donors 
still show evidence of foamy macrophages on lung histology as part of the composite 
score shown (Figure 3.39, Appendix Figure 4). Quantitative studies determining the 
relative expression of alternative activation markers in either the CD11c-DN-TGFβRII 
BMT or IL-10KO BMT mice have not been performed. It is also possible that in these 
transgenic BMT mice, the foamy alveolar macrophages are host-derived cells, as alveolar 
macrophages are only 82%  donor-derived despite our high dose of conditioning (1350 
rads) (170). Future studies may involve the use of congenic markers to determine whether 
these macrophages are donor or host-derived. 
We also report increased oxidative stress in BMT mice at d21 post-infection with 
γHV-68, as shown by increased levels of H2O2 and NO2- in BALF (Figure 3.17). These 
reactive intermediates can promote tissue damage and have been implicated in promoting 
pulmonary fibrosis (131). Reactive nitrogen intermediates have been shown in animal 
studies to stimulate production of TGFβ, a potent pro-fibrotic cytokine (130). 
Accordingly, we find a significant increase in levels of TGFβ in BALF from BMT mice 




oxidative stress in pulmonary fibrosis (101). Whether these reactive intermediates 
upregulate TGFβ expression or are upregulated by TGFβ in this model has not been 
tested. Future studies using anti-oxidant compounds and examining oxidative stress in T 
cell-DN-TGFβRII BMT mice will differentiate between these possibilities and will 
determine a more direct role of oxidative stress in the development of pneumonitis and 
fibrosis in our model. Accordingly, the cellular source of the increased H2O2 and NO2- 
has not been determined, though we hypothesize that the increased presence of 
neutrophils in the alveolar space of BMT mice (Figure 3.13) may contribute.  
Discussion: Altered immune responses post-BMT 
In Figure 3.18, we show that BMT mice are able to recruit inflammatory cells to 
the lung as well as control mice at d7 post-infection with γHV-68. These data correspond 
with previous studies from our laboratory showing that BMT and control mice were able 
to similarly recruit immune cells to the lung in response to Pseudomonas aeruginosa 
infection (59). Thus, we conclude that the inability to control lytic viral replication in 
BMT mice is not related to a defect in immune cell recruitment but rather a deficiency in 
immune cell function.  
We initially hypothesized that the increased viral burden found in the lungs of 
BMT mice could be related to defective antigen presentation. DC are the principal APCs, 
linking innate to adaptive immunity and thus initiating the T cell response to pathogens 
(141).  Our data indicate that BMT BMDCs are phenotypically similar to cells cultured 
from non-transplanted control mice in terms of expression of the costimulatory molecules 




uninfected and infected BMT mice also showed equivalent or higher MHC class II and 
co-stimulatory molecule expression compared to controls (Figure 3.20, Figure 3.21). 
Using an MLR as a general measure of APC function, we found that BMT BMDCs were 
efficient stimulators of T cell proliferation, in some cases even more effective than 
control (Figure 3.19).  To ensure that the potential inhibitory phenotype of the BMT 
APCs was not being lost during in vitro culture of BMDCs, we tested freshly isolated 
splenocytes as stimulators in an MLR.  Similar results were found when irradiated BMT 
spleen cells were used as stimulators (Figure 3.22), suggesting that BMT-derived APCs 
are functional when freshly isolated as well. These results correlate with data from human 
patients undergoing autologous HSCT; it has been shown that DC generated from 
peripheral blood precursors post-transplant are effective stimulators in an MLR (10). 
Indeed, at six months post-transplant, these cells were even more potent APCs than DC 
generated prior to transplant (10).  Thus, we conclude that APCs derived from BMT mice 
are capable of promoting T cell proliferation in vitro, and APC dysfunction is likely not a 
major contributor to the impaired anti-viral response in our BMT model.  
Because of the central importance of  CD4 T cells in controlling lytic γHV-68 
infection (78), we hypothesized that T cell dysfunction may contribute to the impaired 
anti-viral response in BMT mice. Using an MLR as a general measure of T cell function, 
we observed that whole splenocytes and CD4 cells isolated from BMT spleen were 
impaired in their ability to respond in an MLR when compared with cells from non-
transplanted control mice (Figure 3.23). Our findings are similar to clinical data showing 
that T cells from HSCT recipients have impaired responses in an MLR even one year 




vitro is due to their overexpression of TGFβ post-transplant (Figure 3.34), as TGFβ is a 
potent inhibitor of naïve T cell proliferation (82). The fact that we see normal T cell 
accumulation in the lungs in response to γHV-68 at d7 post-infection (that is, no defect in 
proliferation in vivo), may be attributed to the fact that T cells, once activated, are 
refractory to the anti-proliferative effects of TGFβ, correlating with decreased TGFβRII 
expression (177). Additionally, the ability of TGFβ to impair T cell proliferation is also 
abrogated in the presence of strong costimulatory signals (82). It is also possible that the 
overproduction of PGE2 post-BMT (Figure 3.24, (60)) contributes to impaired 
proliferation in the MLR, as PGE2 is a known inhibitor of the MLR response (178). 
MLRs including cyclooxygenase inhibitors to block PGE2 production could be used in 
future studies to test this.  
Previous studies from our laboratory have found that overproduction of PGE2 
post-transplant severely limits alveolar macrophage function, therefore impairing 
immunity to Pseudomonas aeruginosa (60). In addition, PGE2 has been reported to have 
suppressive effects on T cells (178). Thus, we first hypothesized that the impaired 
response to lytic γHV-68 in BMT mice could be attributed to PGE2 overproduction. To 
test this hypothesis, BMT mice were treated with indomethacin, a cyclooxygenase 
inhibitor which blocks PGE2 synthesis. We find that indomethacin treatment does not 
restore control of lytic γHV-68 replication, despite reductions in PGE2 (Figure 3.24). 
Therefore, we conclude that, unlike our bacterial model, overproduction of PGE2 in the 
lung post-transplant does not directly impair anti-viral responses. It is interesting to note 
that differential mechanisms appear to be responsible for impaired immunity to bacterial 




limiting immunity to viral infection, future studies should address the interplay between 
upregulated PGE2 (Figure 3.24) and TGFβ (Figure 3.26) post-transplant in both our viral 
and bacterial models, as TGFβ has been reported to induce cyclooxgenase expression in 
other systems (179, 180).  
In addition to the in vitro proliferation defects of BMT T cells, we have also 
found that CD4 T cell differentiation is altered in BMT mice in response to γHV-68 
infection. At d7 post-infection, BMT mice have decreased numbers of Th1 cells and 
increased Th17 and Treg cells in the lung (Figure 3.25). It is likely that overexpression of 
TGFβ in the lungs post-transplant (Figure 3.26) contributes to the altered T cell 
phenotype in BMT mice. TGFβ has been reported to impair Th1 differentiation by 
decreasing expression of IL-12Rβ2, Tbet, and Stat4, molecules all important for IFNγ 
production by CD4 cells (82). Indeed, we have observed reduced expression of Tbet 
mRNA in T cells from BMT mice (Figure 3.34); BMT T cells also produce increased 
TGFβ post-transplant (Figure 3.34). These data correlate with previous studies showing 
that CD4 cells deficient in Tbet have increased TGFβ production (181). In conjunction 
with IL-6 signaling, TGFβ can induce differentiation of Th17 cells (105). The importance 
of T-cell produced TGFβ in promoting Th17 differentiation and inhibiting Th1 
differentiation has been shown using transgenic mice with a T cell-specific deletion in 
TGFβ (103).  
We found that numbers of CD4+Foxp3+ Tregs were increased in the lungs of 
BMT mice both prior to infection and at d7 post-infection (Figure 3.25).  Tregs are a 
specific subset of CD4 cells which function to suppress effector T cells (149).  In the 




tolerance and suppress GVHD (151). Interestingly, in our model, we have found using 
CD45 congenic transplants that 60% of the Tregs in the BMT lung are host-derived. This 
is striking, as we find that 93% of total lymphocytes in the lung at 5 weeks post-
transplant are donor-derived. These data add to a previous study demonstrating that host-
derived cells comprise the large majority of the Treg compartment in the spleen for a 
prolonged period following syngeneic BMT (155). We also demonstrate that Treg 
numbers increase in a radiation dose-dependent manner (Appendix Figure 2). Thus, our 
data show that Tregs may accumulate (perhaps by homeostatic proliferation of radio-
resistant host Tregs (155)) in direct proportion to the size of the niche created by 
conditioning. However, experiments using congenic donors into CD4KO recipients show 
that in the absence of host-derived Tregs, donor-derived CD4+Foxp3+ cells will expand 
to the same extent as in wild type to wild type transplants (Appendix Figure 5), 
suggesting that there is preferential expansion of Tregs post-transplant regardless of 
source.  
To determine the contribution of the Tregs to impaired anti-viral immunity post-
BMT, we depleted Tregs using anti-CD25 and compared viral host defense in these mice 
or mice treated with an isotype control. Treatment with anti-CD25 effectively reduced the 
levels of CD4+Foxp3+ cells to the levels seen in non-transplanted control mice (Figure 
3.28). However, despite the reduction in Tregs, the ability of the BMT mice to control 
lytic virus was still impaired (Figure 3.27). These data are consistent with recent studies 
demonstrating that adoptive transfer of Tregs into mice receiving an allogeneic BMT 
could limit GVHD, but did not impair the ability of the BMT mice to respond to lethal 




mice have restored control of lytic γHV-68 despite the persistence of increased Tregs 
(Figure 3.37). In sum, we conclude that increased Tregs in the lung post-transplant do not 
impair anti-viral host defense to acute γHV-68 replication.   
We next analyzed whether the increased numbers of Th17 cells in the lungs of 
BMT mice (Figure 3.25) could directly contribute to the impaired response to lytic γHV-
68 infection. IL-17a is a cytokine known to be critical for immunity to many extracellular 
bacteria and fungus infections. The role of IL-17a and Th17 cells in anti-viral responses 
has been less well-studied. It appears that Th17 cells are protective in some viral 
infections, while detrimental in others (172). There are no data to date directly studying 
the role of IL-17a in immunity to γHV-68. Our experiments show that lytic viral load is 
equivalent in non-transplanted wild type and IL-17aKO mice infected with γHV-68. 
Accordingly, transplants performed with IL-17aKO donors showed no difference in lytic 
viral gene expression when compared to transplants performed with wild type donors 
(Figure 3.30). Additionally, we observe increased Th17 numbers in the lungs of T cell-
DN-TGFβRII BMT mice, which have restored control of lytic γHV-68 (Figure 3.37). 
Taken together, we conclude that IL-17a does not play a critical role during the first 7 
days post-infection with γHV-68 and that increased numbers of Th17 cells in the lung are 
not directly impairing control of lytic γHV-68 in our BMT model. We have not 
evaluated, however, whether IL-17a plays a role at later time points, such as in the 
clearance of lytic virus from the lungs or in the establishment of latency. Future studies 
may also define a role for IL-17a in regulating post-transplant cytokine alterations, as IL-
17a has been shown to upregulate PGE2, at least in synovial fibroblasts (182). It is also 




fibrosis (183) phenotype at day 21 post-infection, and future studies will be needed to 
explore this further. 
We next hypothesized that rather than increased Tregs or Th17 cells, it was the 
lack of protective Th1 cells in the lung which was impairing control of lytic viral 
replication in the BMT mice. Indeed, IFNγ expression by CD4 T cells is critical for 
control of γHV-68 replication (77-79). To determine the role of APC cytokine production 
in relation to the decreased Th1 cells in the lung, we isolated BMDCs and lung CD11c-
expressing cells from uninfected BMT and control mice. Upon TLR stimulation, we 
found that BMT APCs had reduced expression of IL-12 compared to control (Figure 
3.31, Figure 3.32). However, CD11c-expressing cells isolated from BMT and control 
lungs at d7 post-infection expressed similar levels of IL-12 (Figure 3.32). To test whether 
the impaired IL-12 production by BMT APCs could impair Th1 differentiation, we set up 
in vitro experiments using BMT or control BMDCs, OVA peptide, and OVA-specific 
OT-II CD4 T cells from a non-transplanted mouse. We found that BMT and control 
BMDCs were able to stimulate similar IFNγ production by CD4 cells in this assay 
(Figure 3.33). These data, in combination with the fact that IL-12 was not reduced in lung 
CD11c-expressing cells following γHV-68 infection, suggest that while IL-12 may be 
reduced at baseline in BMT BMDCs and lung CD11c-expressing cells, its reduction is 
not critical for impairing Th1 responses. Indeed, PBMCs from autologous HSCT patients 
have been reported to produce sufficient IL-12 and efficiently induce IFNγ production in 
vitro (184). We have not studied the mechanism by which IL-12 is reduced in BMT 




levels may be a result of increased PGE2 post-transplant, a known inhibitor of IL-12p35 
and p40 transcription (185).  
Future studies may evaluate the role or function of antigen presentation by B cells 
post-transplant, as these cells express MHC class II and may be important contributors to 
the T cell response in our model. While we do find that unfractionated splenocytes are 
efficient stimulators of an MLR response (Figure 3.22), we have not carefully isolated B 
cells and characterized their response. B cells are important antigen-presenting cells, and 
their proliferation and phenotype are indeed known to be affected by the presence of 
TGFβ (82). These cells may also be sources of TGFβ and IL-10, mediators which are 
both upregulated in our model.  
Discussion: Effects of blocking TGFβ signaling in murine BMT  
To determine whether TGFβ was directly inhibiting Th1 differentiation (82) and 
therefore impairing control of γHV-68 replication in the BMT setting, we set up 
transplants using T cell-DN-TGFβRII as donors. Thus, we set up a model system where 
donor-derived T cells in the BMT setting would be non-responsive to TGFβ signaling 
(104). We report that blocking TGFβ signaling in T cells in the BMT setting is sufficient 
to control lytic γHV-68 replication and restore numbers of Th1 cells in the lung at d7 
post-infection (Figure 3.35, Figure 3.36 ). In this regard, our results are similar to a study 
using T cell-DN-TGFβRII mice showing that TGF-β-mediated inhibition of Th1 
differentiation led to increased susceptibility to Leishmania major in Balb/c mice (17). 
We conclude that TGFβ limits protective Th1 responses to γHV-68 lytic replication in 




Furthermore, we find that blocking TGFβ signaling in T cells in the BMT setting 
leads to a dramatic reduction in inflammation, fibrosis and lung histology score (Figure 
3.39). These data suggest direct or indirect involvement of T cells in the development of 
pneumonitis and fibrosis in this model. The observation that T cell TGFβ signaling is 
important for fibrosis development has been made previously in a study using T cell-DN-
TGFβRII mice in a mouse model of chronic allograft rejection (183). Our data suggest 
that TGFβ limits Th1 responses to lytic γHV-68 infection in the BMT setting, thus 
causing an increase in lytic viral load. We hypothesize that subsequent pneumonitis and 
fibrosis during latent infection results from the enhanced lytic virus insult in wild type 
BMT mice (Figure 3.35), possibly causing increased epithelial cell destruction, the 
unresolved inflammatory response that accompanies the increased lytic viral load, or 
altered wound repair mechanisms to control tissue damage. The T cell-DN-TGFβRII 
BMT mice express decreased levels of TGFβ1 prior to infection compared to wild type 
BMT mice (Appendix Figure 6) and have restored numbers of Th1 cells in response to 
lytic γHV-68 infection (161). Thus, it is likely that the improved host response to the lytic 
infection in the T cell-DN-TGFβRII BMT mice may account for the improved 
pneumonitis phenotype noted in these mice at day 21 post-infection. It is interesting to 
note the persistence of increased Th17 cells in the lungs of the T cell-DN-TGFβRII BMT 
mice (Figure 3.37), as TGFβ has been considered an important factor in the development 
of T cells (105). This result is supported by a recent study showing that TGFβ is not 
directly necessary to promote Th17 differentiation (186). 
We also note a modest, but significant reduction in lung histology score in BMT 




promoter (Figure 3.39). We find that CD11c-DN-TGFβRII BMT mice have high lytic 
viral loads at d7 post-infection which are similar to wild type BMT mice (Figure 3.38).  
These data indicate that TGFβ signaling plays little role in CD11c-expressing cells to 
control lytic infection. However, the fact that the CD11c-DN-TGFβRII BMT mice have a 
modestly improved pneumonitis phenotype suggests that some CD11c-expressing cell 
type may influence development of lung pathology at later time points despite a lytic 
infection level that is similar to wild type BMT mice. We have not analyzed whether the 
improved phenotype of the CD11c-DN-TGFβRII BMT is due to blockade of TGFβ 
signaling in lung macrophages, dendritic cells or natural killer cells; however, foamy 
alveolar macrophages were present in the CD11c-DN-TGFβRII BMT lungs.  Whether 
there are quantitatively fewer alternatively activated macrophages in these mice remains 
a formal possibility and will require further study.  We have not analyzed the T cell 
response in the CD11c-DN-TGFβRII BMT mice. While we do not find an improvement 
in lytic viral load, we do find a modest reduction in pneumonitis and fibrosis, which 
could be explained by the ability of the mice to prevent viral reactivation more efficiently 
than wild type BMT mice. It has been shown that non-transplanted CD11c-DN-TGFβRII 
mice have increased levels of innate IFNγ, derived from NK cells, which can affect T cell 
responses (114). Future studies may address these possibilities in our BMT model.  
We find that the magnitude of the host defense defect in BMT mice in response to 
lytic γHV-68 is amplified with increasing viral challenge (Figure 3.3), suggesting that the 
immune response becomes overwhelmed with increased pathogen exposure. We 
hypothesize that this is due to the limiting effects of TGFβ on a protective Th1 response. 




severe pneumonitis and fibrosis during virus latency (Figure 3.40), supporting the 
hypothesis that increased lytic replication is a major contributor to later development of 
lung pathology.  
Taken together, our data support a model where increased TGFβ post-BMT, 
possibly due to conditioning-induced epithelial cell damage in the lung, limits a 
protective Th1 response, leading to a substantial increase in lytic γHV-68 replication. The 
enhanced viral replication leads to increased lung cell damage, causing unresolved 
inflammation, oxidative stress, and dysregulated wound repair mechanisms including 
increased TGFβ and alternatively activated macrophages even after lytic replication has 
subsided in the lung.  
Implications and Contributions to Field 
Data from these studies provide new insights into impaired anti-viral immune 
responses and pneumonitis development post-BMT. Specifically, the major contributions 
of our studies to the HSCT field include new insight into mechanisms of impaired anti-
viral immunity post-HSCT, development of a novel model system of post-transplant 
pneumonitis, and defining a role of TGFβ in impairing immunity post-transplant.  
Mechanisms of increased susceptibility to viral infections post-HSCT have 
largely been attributed to the presence of GVHD, immunosuppressive drug therapy, and 
lymphopenia post-transplant. Our studies now add an additional mechanism, providing 
direct evidence that development of transplanted cells in a conditioned host can result in 
significant alterations in immune response. Importantly, we observe impaired anti-viral 




immunosuppressive drug therapy. In our reconstituted syngeneic BMT model, we report 
reduced proliferative capacity of naïve T cells from BMT mice, as well as altered T cell 
differentiation in response to virus infection. These data add to previous studies from our 
laboratory showing that alveolar macrophage function is significantly impaired in murine 
syngeneic BMT (60). Thus, our studies provide further support that the susceptibility to 
pulmonary infection post-HSCT can be attributed to a number of factors, including the 
transplantation and conditioning procedure itself.  
A major contribution of this work is the development of a novel model of post-
transplant pneumonitis and fibrosis. Pneumonitis is a serious complication of HSCT, with 
reviews having estimated the incidence of IPS to be 7.6-10.6% of allogeneic patients and 
5.7-5.8% of autologous patients (36, 187). Both IPS and bronchiolitis obliterans are 
considered to be non-infectious pulmonary complications of HSCT, based on the inability 
to find active infection in these patients. We find that while the pathology in our BMT 
model is virus-induced, it does not manifest until virus latency, when there is very little 
detectable active virus replication occurring (Figure 3.6, Figure 3.8). Thus, our model 
suggests the possibility that pneumonitis development in HSCT patients may result from 
unresolved inflammation and tissue damage induced by a previous active infection. 
Additionally, our model is unique in that we observe the development of severe lung 
pathology in the absence of alloreactive cells. Murine models of IPS have been studied 
almost exclusively in the allogeneic setting, associating GVHD development with the 
appearance of lung pathology that resembles IPS. In these models, syngeneic BMT mice 
used as controls have normal lung histology several weeks post-transplant, reflecting 




direct evidence that lung damage from a previous active infection may promote later 
development of pneumonitis and fibrosis, especially in the autologous setting, where 
alloreactive T cells are absent.  
Studies have indicated that HSCT patients may have reduced pulmonary function 
post-transplant, with abnormalities persisting long-term (31, 32). Specifically, one study 
found that pediatric HSCT patients had reduced pulmonary function 3-6 months post-
transplant, and despite partial recovery, patients had not returned to their pre-transplant 
values even 12-24 months post-transplant (21). Our data indicates that reduced 
pulmonary function post-HSCT may be related to unresolved inflammation and/ or lung 
damage induced by a previous pulmonary infection, as BMT mice in our model had 
reduced oxygen saturation at d21 post-infection with γHV-68 (Figure 3.15) and 
pathology which persisted even at 7 weeks post-infection (Figure 3.12). 
Additionally, our studies have uniquely described a role of TGFβ in limiting anti-
viral immune responses and promoting pneumonitis post-BMT. Previous work in a 
murine allogeneic GVHD model showed that induction of HSV-1 pneumonitis at late 
time points post-transplant was also mediated by effects of TGFβ (123). While our model 
also implicates TGFβ in promoting pneumonitis, there are several important differences 
between the models. First, pneumonitis in the HSV-1 model developed at days 5-7 post-
infection and involved periluminal, but not parenchymal inflammation and no indication 
of fibrosis. Additionally, the authors concluded that pneumonitis in the HSV-1 model 
resulted from GVHD, as non-GVHD allogeneic BMT mice did not develop lung 




speculate that fibrosis and lung pathology in the non-GVHD allogeneic mice would 
manifest at later time points following HSV-1 infection as well.  
Our studies also have significant implications for interpretation of experiments 
using bone marrow chimeras. Our laboratory has shown numerous alterations which 
occur simply as a result of TBI and transfer of cells. Thus, it is critical that bone marrow 
chimera experiments are tightly controlled. Experiments should first compare wild type 
into wild type and non-transplanted wild type mice as controls to understand how the 
phenotype being studied may be affected by TBI and transplant. In our model, we find 
significant changes in the immune response occur even at 5 weeks post-transplant, the 
time point when our studies were performed.  
Limitations of Model System 
Despite the advantages of controlled study, there are several important limitations 
of using a murine model to understand immune responses post-HSCT. Conditioning in 
murine models has traditionally been via the administration of TBI (58), partially due to 
the limitations of chemotherapy in promoting donor cell reconstitution post-HSCT (170) 
and due to chemotherapy-related morbidity in mice. While the administration of TBI in 
combination with cyclophosphamide has been considered the “gold standard” among 
conditioning regimens, non-TBI conditioning regimens are now common in human 
HSCT recipients (24). While chemotherapeutic agents and TBI have both been 
implicated in promoting lung damage in humans (33-35), it is unclear whether the 
mechanisms by which TBI affects lung cells in our murine model reflects the 




shielding may be used to protect organs from TBI-related damage in human patients, 
while we have not used shielding in our mouse model. Our model also does not allow us 
to discriminate the effects of cell transfer and reconstitution versus the direct effects of 
the conditioning regimen, limiting more careful mechanistic study. Future studies may 
include transfer of cells into SCID mice to determine whether the effects are due to 
transfer, conditioning, or both. Because we do not achieve 100% donor cell reconstitution 
in our model (170), transplants using congenic markers might be used to study the 
differences in donor versus host T cells to give an idea of whether conditioning or 
transfer of cells causes changes.  
Additionally, we use naïve mice in our studies as both bone marrow donors and 
recipients. HSCT patients receive transplants as a curative option for many disorders, 
particularly malignancies and, as such, are not healthy when transplanted. The effects of 
previous chemotherapy, disease, and infections which may be present in humans (and 
contribute to susceptibility to infection) are not reflected in our model. Transplant donors, 
also, will be antigen-experienced and may have a wider repertoire of memory cells, 
especially if transplanted cells are harvested from the peripheral blood. Accordingly, our 
studies use γHV-68 infection as a model to understand how anti-viral immunity is altered 
post-transplant. However, in human patients, disease associated with herpesvirus 
infections generally occurs as a result of viral reactivation, either from donor cells or 
preexisting infection in the recipient. Future studies should address immunity to 
reactivation of virus infection, since reactivation, not primary infection, is the principal 




The study of T cell responses post-transplant in a murine model is somewhat 
limited, as we do not see the inverted CD4/CD8 ratio in our model that is observed in the 
peripheral blood of HSCT patients post-transplant (54-56). This fact may be due to 
intrinsic differences in reconstitution between humans and mice or could be that lung 
tissue cells differ in number compared to peripheral counts.  
Long-term studies in T cell-DN-TGFβRII BMT mice in our model are limited, as 
the donor mice develop spontaneous autoimmune disease, characterized by inflammatory 
bowel disease and lung infiltration at 3-4 months of age (104). We think that this 
autoimmune response may be quickened in our infected T cell-DN-TGFβRII BMT mice, 
as some mice developed wasting disease even prior to d21 post-infection. 
Finally, while the syngeneic model provides a system to understand how 
conditioning and subsequent transfer of cells leads to alterations in anti-viral immune 
responses, it is unclear whether the mechanisms observed in our model are translatable to 
the allogeneic setting. Many infectious and non-infectious pulmonary complications 
which occur post-transplant are  more common in the allogeneic setting (3, 36, 38), so it 
will be important to determine whether general mechanisms observed in our studies are 
applicable to both autologous and allogeneic transplants. Preliminary data discussed in 
the Future Directions section of this dissertation will address these issues.  
Future Directions 
Our studies establish a murine BMT model wherein transplanted mice have a 
reduced ability to control lytic viral replication, following immune cell reconstitution, 




BMT mice overexpress TGFβ and that blocking TGFβ signaling in T cells in the BMT 
setting is sufficient to restore Th1 responses, control lytic viral replication, and prevent 
severe pneumonitis. For future studies, it will be important to develop a more complete 
understanding of the underlying mechanisms contributing to the increased lytic viral load 
and development of pneumonitis in our BMT model. There are three main lines of 
investigation, supported by preliminary data that we have developed, that will be 
important to study in order to achieve this goal, including developing a more mechanistic 
understanding of the effects of TGFβ on BMT T cells, teasing out which post-BMT 
alterations specifically contribute to pneumonitis development, and understanding how 
these effects translate to allogeneic BMT models.  
Future Directions: BMT T cells and TGFβ   
Data from these studies support a model in which transplant-induced TGFβ 
overexpression skews the phenotype of CD4 T cells away from a Th1 response by 
inhibiting Tbet. For future studies, it will be important to more carefully define the 
mechanisms by which BMT T cells are skewed away from a protective Th1 response in 
vivo and determine how TGFβ mediates its effects. TGFβ is potent regulator of both CD4 
and CD8 T cell differentiation, proliferation, and function (82), and it will be pertinent to 
determine the specific mechanism(s) by which TGFβ limits T cell responses in the BMT 
model.  
Our in vitro assays showed that although BMT BMDCs and lung CD11c-
expressing cells produce decreased IL-12, BMT BMDCs are able to induce efficient 




decreased Tbet (Figure 3.34) and diminished Th1 response to γHV-68 (Figure 3.25) are 
independent of the BMT dendritic cell phenotype. However, an important experiment to 
validate the claim that the deficiency is T cell intrinsic and not dendritic cell-related 
would be to set up analogous assays using either BMT or control CD4 cells as responders 
stimulated with BMT or control dendritic cells. We would expect, based on our model, 
that BMT T cells would have reduced IFNγ production, regardless of whether they were 
stimulated with dendritic cells from a BMT or control mouse. Accordingly, it is 
important to confirm that the T cell phenotype observed in BMT splenic T cells is 
analogous with T cells derived from BMT lungs, as these cells would be exposed to 
different structural cells which may be differentially affected by the conditioning 
regimen. While we do see that reduced Th1 responses in the lung correspond with 
reduced Tbet expression in splenic T cells, there may be location-specific differences. 
Indeed, data from our laboratory indicate that alveolar, but not peritoneal, macrophages 
from BMT mice have functional deficits post-transplant (unpublished observations).   
Next, it will be pertinent to determine how TGFβ may be mediating its effects on 
the T cell phenotype in the BMT setting. TGFβ is known to have several roles in the 
regulation of T cells. In Figure 3.35, we demonstrate that T cell-DN-TGFβRII BMT mice 
have restored control of lytic viral replication compared to wild type BMT mice. This 
correlates with a restoration in numbers of Th1 cells in the lung at d7 post-infection 
(Figure 3.36), a cell type required for efficient control of lytic viral replication (77-79). A 
preliminary experiment shows that lungs from T cell-DN-TGFβRII BMT mice produce 
decreased levels of TGFβ compared to wild type BMT mice (Appendix Figure 6), 




overproduction of TGFβ. This suggests a model wherein TGFβ produced post-transplant 
in the lung, either from structural cells or another cell type, signals T cells to either 
produce increased TGFβ themselves or promote other cell types to produce TGFβ, by a 
positive feedback mechanism (Figure 4.1). Indeed, TGFβ is known to promote its own 
expression (93, 172, 189). In support of this model, we find that splenic CD4 and CD8 T 
cells from BMT mice overproduce TGFβ (Figure 3.34). However, future studies will 
determine whether lung-derived T cells from BMT mice also overproduce TGFβ. It will 
be important to test whether T cell-produced TGFβ is sufficient to impair anti-viral 
immunity. This can be analyzed by setting up transplants using bone marrow from mice 
which have a T cell-specific deletion of the Tgfβ1 gene (103). Reconstituted, donor-
derived T cells in these transplanted mice would not be able to produce TGFβ1. 
Analyzing lytic viral loads and T cell differentiation in these mice in the BMT setting 
will provide insight into the role of T cell-produced TGFβ in our model. Additionally, 
determining production of TGFβ by resident lung cells in these mice would provide a 
better understanding of mechanism of TGFβ upregulation. Long-term studies may be 
somewhat limited, similar to the T cell-DN-TGFβRII BMT mice, as the donor strain 
(lacking T cell Tgfb1) develops multiorgan autoimmunity with spontaneously 





Because of the importance of Th1 cells in lytic γHV-68 infection, our studies have 
largely focused on CD4 cells post-transplant. However, TGFβ has important effects on 
CD8 cells as well, including inhibiting expression of perforin and FasL (82). TGFβ can 
also reduce IFNγ production by CD8 cells via inhibition of Tbet (190). CD8 cells are an 
important, expanded population during γHV-68 latency. Thus, future studies should 
address the effector function of CD8 cells isolated from BMT mice. We do find that CD8 
cells from BMT mice produce increased levels of TGFβ post-transplant (Figure 3.34). 
Future studies may include in vitro analysis of CD8 cytotoxic function. If effector 
function of BMT CD8 cells is reduced, we might hypothesize that inclusion of a 
neutralizing TGFβ antibody in these assays would restore function. In vivo studies should 
include a kinetic analysis of perforin, IFNγ, and FasL expression by CD8 cells in BMT 
and control mouse lungs following γHV-68 infection. This would give some insight into 
Figure 4.1 Potential mechanism for overproduction of TGFβ in the lung 
post-BMT. Preliminary data support a model where TGFβ produced by 
epithelial or other cell types in the lung affects T cell production of TGFβ 
and/or T cell induction of TGFβ production by other cell types in the lung. 




whether a TGFβ-induced phenotype is present in BMT CD8 cells. Additionally, future 
studies should evaluate the contribution of CD8 cells in the restoration of lytic anti-viral 
immune responses in T cell-DN-TGFβRII BMT mice, as TGFβ signaling is blocked in 
both CD4 and CD8 T cells in these mice. Studies involving adoptive transfer of CD8 
cells from γHV-68-infected BMT or control mice into naïve mice and challenging with 
γHV-68 may provide insight into the function of these cells. 
Our studies look at total TGFβ production in the lungs post-BMT by ELISA 
(Figure 3.26). This shows that BMT mice have more total TGFβ available for activation 
and potential roles in immune responses. However, we did not directly measure the active 
protein present in the lungs. We find that despite increasing susceptibility to γHV-68 with 
increasing irradiation dose (Figure 3.2), total TGFβ levels in the lung are similarly 
increased between mice conditioned with 650, 900 or 1350 rads (Appendix Figure 2); we 
do not yet know whether active TGFβ levels increase in parallel with radiation dose. We 
hypothesize that there may be more active TGFβ present post-transplant, perhaps through 
dysregulation of integrins as a result of conditioning. It is also possible that T cell 
responsiveness to TGFβ post-transplant may be altered and that this may also be radiation 
dose-dependent. This can be analyzed by determining levels of TGFβ receptor expression 
and SMAD phosphorylation as a result of TGFβ treatment of T cells from control mice 
and BMT mice conditioned with 650, 900, or 1350 rads. We would hypothesize that 
sensitivity to TGFβ may increase with increasing conditioning. Preliminary studies 
examined the expression of the TGFβ1 receptors I and II on splenic T cells from control 
and BMT mice and found no differences; interestingly, however, treatment of splenic T 




approximately 3 fold greater induction in COX-2, a known TGFβ1-responsive gene (191) 
over unstimulated levels in the BMT T cells when compared to control T cells. Thus, 
there may be increased senstitivity to TGFβ signaling in T cells post-BMT due to 
alterations in intracellular signaling pathways. 
Finally, future studies may address the possibility that there is a limited T cell 
receptor repertoire post-transplant, which may contribute to impaired response to γHV-
68. While we find that there is no decrease in numbers of virus-specific CD8 cells in 
BMT mouse lungs at d14 post-infection (Appendix Figure 7), this does not rule out the 
possibility that a limited CD4 repertoire is contributing to impaired responses. Indeed, 
homeostatic proliferation post-transplant has been described to limit the T cell repertoire 
in HSCT patients even 3 years post-transplant (56). This can be studied using PCR to 
analyze variability in CDR3 lengths in T cells post-transplant compared to non- 
transplant control cells (56).  
Future Directions: Mechanisms of Pneumonitis Development 
Our data describe severe pneumonitis and fibrosis which occur during virus 
latency, characterized by inflammation, presence of foamy alveolar macrophages, 
oxidative stress, and altered cytokine profile. While we find that pneumonitis 
development can be largely inhibited by blocking TGFβ signaling in T cells in the BMT 
setting, we have not explored the specific mechanisms that contribute to the development 
of lung pathology. Future studies should determine the relative contribution of these 




We have found that alveolar macrophages from BMT mice at d21 post-infection 
with γHV-68 as a population express increased levels of both the alternative activation 
marker Arginase 1 as well as increased iNOS (Figure 3.16). Immunohistochemistry 
and/or flow cytometry studies should discriminate whether individual macrophages are 
expressing both markers or whether there are 2 distinct populations of macrophages. 
Additionally, the relative contribution of these macrophages to the lung pathology 
phenotype can be determined by performing similar studies on macrophages from T cell-
DN-TGFβRII BMT mice. While we do find the presence of foamy alveolar macrophages 
in these mice, we have not analyzed whether they express markers of alternative 
activation. More direct experiments to test the role of these macrophages in promoting 
fibrosis should involve adoptive transfer of alveolar macrophages from BMT mice into 
non-transplanted control mice infected with γHV-68. We would hypothesize that if 
foamy alveolar macrophages are the main contributor to pneumonitis and fibrosis 
development, adoptive transfer of these cells would induce lung pathology in the 
infected, non-transplanted mice. 
We have found increased levels of both H2O2 and NO2- in the alveolar space of 
BMT mice at d21 post-infection with γHV-68 (Figure 3.17). To determine whether 
oxidative stress may be contributing to lung pathology in our model, BMT mice infected 
with γHV-68 should be treated with anti-oxidants such as n-acetylcysteine (192). We 
hypothesize that anti-oxidant therapy would minimize lung damage, resulting in less 
severe pathology in our latently-infected BMT mice. The presence of H2O2 and NO2- in T 
cell-DN-TGFβRII BMT mice should also be determined, as these mice have significantly 




Future studies should also determine whether the altered cytokine expression 
noted in BMT mice contributes to γHV-68-induced pathology. We note increased levels 
of IL-10 production by BMT lung cells at d21 post-infection (Appendix Figure 4). We 
initially hypothesized that IL-10 may be contributing to pathology via induction of 
alternatively activated macrophages (176); however, a preliminary experiment shows that 
mice transplanted with IL-10KO bone marrow still develop pneumonitis, with a 
pathology score of approximately 8 out of 11 (Appendix Figure 4). Wild type BMT mice 
were not included as controls in this preliminary study, so it is unclear whether there is 
some protection in these mice. The overproduction of IL-10 in BMT mouse lungs during 
virus latency may be secondary to enhanced TGFβ production by T cells (193).  
Although we do not see any reduction in lytic viral load in BMT mice 
transplanted with IL-17aKO bone marrow compared to wild type BMT mice (Figure 
3.30), we have not ruled out the possibility IL-17a could play a role in promoting 
pneumonitis and fibrosis. Indeed, IL-17a has been implicated in promoting fibrosis in 
several model systems, including a chronic allograft model (183), a model of 
hypersensitivity pneumonitis and lung fibrosis (194), and bronchiolitis obliterans 
development in lung transplant patients (195). However, we think the overall contribution 
of IL-17a to fibrosis development in our model may be limited, as T cell-DN-TGFβRII 
BMT mice have increased numbers of Th17 cells similar to wild type BMT, yet have a 
significant reduction in fibrosis development (Figure 3.37, Figure 3.39). Future studies 
using IL-17aKO mice as transplant donors should determine whether IL-17a promotes 




While we find that blocking TGFβ signaling in T cells is sufficient to significantly 
reduce development of pneumonitis and fibrosis (Figure 3.39), it is important to more 
carefully assess the timing of the effects of TGFβ in our model system. It is possible that 
increased TGFβ may have effects on our lung pathology phenotype during immune cell 
reconstitution, lytic infection, or latent infection. These experiments may be performed 
using a neutralizing TGFβ antibody given at various time points prior to and post-
infection. Using anti-TGFβ will also be advantageous in that its administration can be 
titered to reduce, but not completely abrogate, TGFβ levels in our BMT mice. This may 
avoid and/ or delay the effects of autoimmunity which develop in our T cell-DN-
TGFβRII BMT mice. It would also more closely mimic a potential therapeutic regimen 
that could be useful in humans. 
It is interesting to note that the virus-induced pathology observed in our BMT 
mice does not appear during the lytic phase, but rather manifests later, during virus 
latency. It is plausible that the lung pathology observed may be due to increased viral 
reactivation. To test this idea, we will infect BMT and control mice with wild type γHV-
68 or a mutant γHV-68, lacking ORF72, a viral cyclin-D homolog that is required for 
reactivation from latency (ΔORF72). The ΔORF72 mutant replicates normally in the lung 
in vivo during acute infection and establishes normal latent viral load, but it does not 
efficiently reactivate from latency (196). If virus-induced lung pathology in BMT mice 
occurs due to increased viral reactivation, then we would expect a significant reduction in 
histology score in BMT mice infected with ΔORF72. Increased viral reactivation could 
possibly be due to decreased effector function of CD8 T cells in the BMT setting. It may 




prevent virus reactivation from latency; studies have shown that depleting IFNγ 
following the establishment of latency leads to enhanced reactivation(172). It is possible 
that the increased CD8 T cells in the alveolar space of BMT mice during virus latency 
(Figure 3.14) are either protective, preventing virus reactivation, or are 
immunopathological, causing damage to the lung. If they are functionally suppressing 
virus reactivation, it is curious why there would be increased numbers of CD8 cells in the 
BMT lungs, as the latent viral load between BMT and control lungs is similar (Figure 
3.5). However, it may be that effector function of these CD8 cells is limited by the 
increased levels of TGFβ (82) in the alveolar space at d21 post-infection (Figure 3.17), 
thus having increased numbers in an attempt to maintain viral latency.  
In addition, future studies should carefully characterize whether it is the delay of 
lytic clearance or the absolute lytic viral titers that determine the development of 
pneumonitis and fibrosis. Mutant viruses that have an inability to establish latency or the 
ability to establish latency without development of lytic replication may be useful in 
making these determinations (69, 197).  
Our studies have not evaluated the role of B cells in the development of 
pneumonitis and fibrosis during virus latency. B cells are the main reservoir for latent 
γHV-68 in vivo, and these cells are important for prevention of disease during persistent 
infection (69). The antibody response to γHV-68 infection is largely non-specific for viral 
antigens, and it is unclear what role these antibodies play in protection from disease. It 
has been postulated that the importance of B cells during chronic infection may involve 
their antigen-presenting function (69). Future studies may include assessment of the 




vitro, followed by analysis of the antibody response by BMT mice to γHV-68 infection. 
Indeed, it has been shown that B cells from HSCT patients are impaired in their ability to 
produce isotype-switched antibody for years post-transplant (9). However, it may be 
more relevant to functionally characterize the ability of B cells from BMT mice to act as 
antigen-presenting cells, using in vitro assays such as MLR. Additionally, flow cytometry 
may be used to analyze the phenotype and expression of costimulatory and MHC 
molecules on B cells in BMT mice during virus latency. 
 We are also interested in understanding whether the severe pneumonitis and 
fibrosis phenotype that we observe in our BMT model can be induced by pathogens or 
inflammatory stimuli other than γHV68. Unlike γHV-68, a preliminary experiment from 
our laboratory shows that BMT and control mice have similar control of lytic murine 
CMV (MCMV) infection, a member of the β-herpesvirus family (Appendix Figure 8). 
This may be related to the importance of NK cells in controlling lytic replication of 
MCMV. We have not evaluated the functionality of NK cells in our murine model; 
however, human studies have indicated that NK cell function is not diminished post-
transplant (8). Looking at whether pneumonitis and fibrosis develop during latent MCMV 
infection in BMT mice would provide insight into whether uncontrolled viral replication 
is the main factor contributing to pneumonitis. We would anticipate that if uncontrolled 
lytic replication was, in fact, the mechanism, then BMT mice in our model would not 
develop pneumonitis in response to MCMV latency.  
 Additionally, we have not identified the role of chemokines in the recruitment or 
persistence of inflammatory cells to the BMT mouse lung in response to γHV-68 




contributed to pathology development, as transplants using CCR2KO donors had a 
significant reduction in lung pathology. MCP-1 was also found to be increased in BALF 
from allogeneic HSCT patients with IPS (189). Additionally, increased MCP-1 levels 
were observed in a model of lung injury after high dose chemotherapy and syngeneic 
BMT in mice (198).  A preliminary experiment in our model looking at chemokine 
expression in collagenase-digested lungs from BMT and control mice at d21 post-
infection indicates no increase in chemokine levels in BMT lungs, with a significant 
decrease in MCP-1 (Appendix Figure 9). However, the majority of cells in this cell 
suspension are leukocytes, and future studies should evaluate chemokine and receptor 
expression on structural cells as well. Additionally, it would be pertinent to investigate 
the expression of chemokines throughout the post-transplant and post-infection time 
periods in our model to understand how chemokine expression may be altered in BMT 
lungs. We might expect chemokine levels to be increased during the initial increased 
accumulation of inflammatory cells in the lung, which occurs between d7 and d14 post-
infection (Figure 3.6).   
Future studies may also determine whether the pneumonitis and fibrosis 
phenotype persist when BMT mice are conditioned with chemotherapeutic agents, rather 
than TBI, prior to transplant.   
Future Directions: Allogeneic Models 
We are also interested in understanding whether the results from our studies are 
translatable to allogeneic BMT models. Performing experiments in allogeneic models 




pneumonitis development between syngeneic BMT and BMT complicated with the 
presence of alloreactive T cells. Clinically, both infectious and non-infectious pulmonary 
complications are more frequent in the allogeneic setting (3); this is likely related both to 
alloimmunity as well as immunosuppressive drug regimens to mitigate GVHD.  
We have performed some preliminary studies looking at γHV-68 infection in a 
fully allogeneic murine BMT model. Our results show that allogeneic BMT mice have an 
increase in lytic viral replication, similar to syngeneic BMT mice as shown by increased 
expression of the lytic viral genes gB and DNA polymerase in the lung at d7 post-
infection (Appendix Figure 10). Allogeneic BMT mice also have similar increases in 
TGFβ and Tregs in the lung (Appendix Figure 11). Interesting, these mice do not show 
signs of GVHD during the post-transplant time period, as there is no substantial weight 
loss compared to syngeneic BMT mice (Appendix Figure 10).  Thus, we hypothesize that 
the decreased control of lytic viral replication at d7 post-infection in the allogeneic BMT 
mice may be due to mechanisms similar to what we observe in our syngeneic model. 
Future studies in the allogeneic model should include an analysis of Th1 cells in the lung 
in response to lytic γHV-68.  
However, our preliminary studies do show significant differences between 
syngeneic BMT and allogeneic BMT mice during virus latency. We have found that 
γHV-68 latency is lethal in allogeneic BMT mice by d20 post-infection, with severe 
weight loss during the course of infection (Appendix Figure 12). This is in contrast with 
control and syngeneic BMT mice which survive infection with 5x10
4
 pfu γHV-68. Future 
studies should differentiate between whether the allogeneic BMT mice succumb because 




lytic replication. Histology studies at d14 post-infection in these allogeneic BMT mice do 
indicate the development of pneumonitis and fibrosis not observed in uninfected 
allogeneic BMT mice (Appendix Figure 13). We hypothesize that stimulation of the 
immune response to γHV-68 leads to activation of alloreactive T cells in our model. 
Indeed, TLR9 activation has been noted to promote GVHD in murine models (199), and 
as a DNA virus, we would expect that TLR9 would be activated during γHV-68 
infection. 
Future studies should monitor these mice post-infection and look at histology of 
gut as well as lungs to determine whether they succumb to pulmonary-related pathology 
or gut-related pathology which is a major GVHD target. In these allogeneic BMT mice, 
we have not determined whether there is increased TGFβ or indication of oxidative stress 
as we see in the syngeneic BMT model. Experiments looking at the role of TGFβ in 
promoting pneumonitis and susceptibility to γHV-68 infection in allogeneic BMT models 
is complicated, as TGFβ is important in suppressing acute GVHD effects (117, 120). 
Thus, preliminary experiments in our laboratory using T cell-DN-TGFβRII donors on 
C57BL/6 background into Balb/c recipients ended in lethality. It may be important to 
challenge these allogeneic BMT mice with a lower dose of virus or perform experiments 
across a minor MHC mismatch. These modifications may allow survival of the allogeneic 
BMT mice post-infection and will allow analysis of immune mechanisms.  
Recent studies have shown some success in using etanercept, blocking TNF, in 
IPS treatment in allogeneic patients (38, 93). Because of this, we were curious to know 
whether TNFα levels may be increased in our pneumonitis model at d21 post-infection. 




setting, both in whole lung homogenates and in alveolar macrophages (Appendix Figure 
14). Future studies should address whether TNFα expression is altered during 
pneumonitis development in allogeneic BMT mice latently infected with γHV-68. If 
TNFα is increased in allogeneic BMT mice in our model, this will provide important 
insight into the possible differences between pneumonitis pathogenesis in autologous and 
allogeneic HSCT recipients.  
Concluding Remarks 
In sum, our studies have established a murine BMT model that has allowed us to 
analyze alterations in immune responses to viral infection and pneumonitis development 
which occur post-transplant, in the absence of GVHD or immunosuppressive therapy. We 
find that cells transplanted into a conditioned host have significant phenotypic changes 
compared to cells isolated from a non-transplanted host, leading to impaired control of 
lytic viral infection and later development of pneumonitis and fibrosis during virus 
latency. Our model may provide important insight into the mechanisms of pneumonitis 
development in HSCT patients, as we show that factors other than alloresponses can 


















Appendix Figure 1. Very little IL-4 and IL-13 expression in the lung at d21 
post-infection. BMT and control mice were infected with 5x10
4
 pfu γHV-
68 and lungs were harvested at d21 post-infection. A. and B. Collagenase-
digested cells from BMT and control mice were cultured at 5x10
6
 cells per 
mL for 24h, either untreated, plus ConA or LPS (n=5 per group) and 
analyzed by ELISA for IL-4 or IL-13 (n=5 per group; n.d. = not 
detectable). C. 5x10
6
 BAL cells were cultured overnight, harvested for 
RNA and analyzed for IL-13 and IL-14 by real time RT-PCR (u.d. = 
undetermined, n=4 per group). D. Alveolar macrophages were enriched by 
plastic adherence in serum-free media for 1h. Cells were then harvested 






Appendix Figure 2. Treg numbers in the lungs of syngeneic BMT mice are 
dependent on radiation dose, while levels of TGFβ1 are not. Syngeneic 
transplants were performed in mice receiving 650, 900, or 1350 rads. A. Levels 
of total TGFβ1 were analyzed in the lungs of BMT mice by ELISA; TGFβ1 
was significantly increased in all conditioning regimens (data combined from 2 
experiments; n= at least 9 per group).  B. At d7 post-infection with γHV-68, 
right lungs were digested in collagenase and analyzed for expression of CD4 
and Foxp3 by flow cytometry. There were significantly elevated numbers of 
Tregs in mice conditioned with 900 and 1350 rads compared to non-transplant 






Appendix Figure 3. Tbet and eomesodermin expression in 
BMT T cells decreases with increasing radiation dose. 
Transplants were performed in mice receiving 650, 900, or 
1350 rads. T cells were enriched from the spleen by CD19 
depletion, and cells were cultured overnight. Expression of 
Tbet and Eomesodermin was determined using real time RT-





Appendix Figure 4. BMT mice overexpress IL-10 in the lungs at d21 post-
infection. A. Lungs from BMT and control mice at d21 post-infection with 
5x10
4
 pfu γHV-68 were digested in collagenase. 5x10
6
 cells were cultured 
for 24h without treatment or with ConA or LPS. Cell supernatants were 
analyzed for IL-10 by ELISA. B. Mice transplanted with bone marrow from 
an IL-10KO donor were infected with 5x10
4
 pfu γHV-68. At d21 post-
infection, lungs were harvested for histology and scored (n=5). Wild type 
BMT mice were not infected in parallel for this preliminary experiment, but 






Appendix Figure 5. Lung Tregs expand post-BMT even in absence of 
host-derived CD4 cells. CD45.2 recipients (either wild type 
C57BL/6 or CD4KO) were conditioned with 1350 rads and were 
transplanted with whole bone marrow from CD45.1+ (Ly5.2) donors.  
Mice were infected with 5x10
4
 pfu γHV-68. At d7 post-infection, 
right lungs were digested with collagenase and analyzed for 
expression of CD4 and Foxp3 by flow cytometry (n=5 per group; 








Appendix Figure 6. T cell-DN-TGFβRII BMT mice have reduced lung 
TGFβ compared to wild type BMT mice. Lung homogenates from 
uninfected wild type BMT or T cell-DN-TGFβRII BMT mice were 






Appendix Figure 7. BMT and control lungs have similar 
numbers of tetramer-positive CD8 cells on d14 post-infection. 
Lungs were harvested from BMT and control mice at d14 post-
infection with 5x10
4
 pfu γHV-68 and digested in collagenase. 
Cells were then stained for flow cytometry using CD8 antibody 
and tetramers loaded with H-2K(b)- and H-2D(b)-restricted 







Appendix Figure 8. BMT and control mice have similar control of MCMV 
infection. Control and BMT mice were infected i.n. with 5x10
4
 pfu 
MCMV. At d7 post-infection, lungs were homogenized and analyzed by 





Appendix Figure 9. BMT collagenase-digested cells do not have increased 
chemokine expression at d21 post-infection. Collagenase-digested lungs from 
BMT and control mice at d21 post-infection with 5x10
4
 pfu γHV-68 were 
harvested for RNA. Expression of chemokines was determined using real time 







Appendix Figure 10. Allogeneic BMT mice show increased susceptibility to 
γHV-68 in absence of GVHD. A. Mice receiving syngeneic or allogeneic 
(Balb/c  C57BL/6) BMT were weighed twice a week as a measure of 
GVHD for 5 weeks post-BMT (n=5 syngeneic, 10 allogeneic per time point; 
data representative of 2 independent experiments). B. and C. Left lungs were 
harvested from control and allogeneic BMT mice at d7 post-infection with 
γHV-68, processed for RNA, and analyzed for expression of lytic viral genes. 
Viral gene expression was significantly increased in allogeneic BMT mice 
when compared to non-transplanted control mice (p=0.0225 for viral capsid 
gene, p=0.0367 for viral DNA polymerase; n= 3 control, 5 allogeneic BMT, 






Appendix Figure 11. Allogeneic BMT mice have increased TGFβ1 and 
increased Treg numbers in the lungs. A. TGFβ1 levels in the lungs of 
syngeneic and allogeneic BMT mice were determined by ELISA. Both 
BMT groups expressed similar increases in TGFβ1 levels (n= 3 control, 3 
syngeneic, and 5 allogeneic). B. Control, syngeneic, and allogeneic BMT 
mice were infected with 5x10
4
 pfu γHV-68. At d7 post-infection, right 
lungs were digested in collagenase and analyzed by flow cytometry for 
expression of CD4 and Foxp3. CD4+Foxp3+ cells were significantly 
increased in both syngeneic and allogeneic BMT mice compared to non-








Appendix Figure 12. Allogeneic BMT mice succumb to γHV-68 
infection. Control, syngeneic, or allogeneic BMT mice were infected 
with 5x10
4
 pfu γHV-68, and weights and survival were monitored for 





Appendix Figure 13. Allogeneic BMT mice display virus-induced pathology at d14 
post-infection. Lungs were harvested for histology from uninfected allogeneic 
BMT mice (8 weeks post-BMT) or at d21 post-infection with 5x10
4
 pfu γHV-68. 
Lung sections were stained with H&E or Trichrome. Slides were scored in a 





Appendix Figure 14. BMT lungs and alveolar macrophages express 
decreased TNFα at d21 post-infection. Control and syngeneic BMT mice 
were infected with 5x10
4
 pfu γHV-68 and analyzed at d21. A. Lung 
homogenates were analyzed for TNFα by ELISA (n=3 control, 3 BMT). 
B. Alveolar macrophages were harvested by BAL and enriched by plastic 
adherence. TNFα expression was determined using real time RT-PCR 
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